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Immunomodulatory Effects of Novel Therapies for Stroke 
Aaron A. Hall 
Abstract 
 Each year, approximately 795,000 people suffer a new or recurrent stroke. 
About 610,000 of these are first attacks, and 185,000 are recurrent attacks 
(Carandang et al. 2006).  Currently the only FDA approved treatment for 
ischemic stroke is recombinant tissue plasminogen activator (Alteplase) (Marler 
and Goldstein 2003).  Unfortunately its use is restricted to a short, 4.5 hour, time 
window.  Two promising therapies in the treatment of stroke at delayed 
timepoints are human umbilical cord blood cells (HUCBC) and the sigma 
receptor agonist DTG 
 The first series of experiments were conducted to characterize the effects 
of sigma receptors on various aspects of microglial activation.  Sigma receptor 
activation suppresses the ability of microglia to rearrange their actin cytoskeleton, 
migrate, and release cytokines.  Stimulation of sigma receptors suppressed both 
transient and sustained intracellular calcium elevations associated with microglial 
activation. Further experiments showed that sigma receptors suppress microglial 
activation by interfering with increases in intracellular calcium.  
 An ex vivo organotypic slice culture (OTC) model to was utilized to 
characterize the efficacy of sigma receptor activation and HUCBC therapy in 
xi 
mitigating neurodegeneration in ischemic brain tissue in the absence of the 
peripheral immune system. HUCBC but not DTG treatment reduced the number 
of degenerating neurons and the production of microglia derived nitric oxide in 
slice cultures subjected to oxygen glucose deprivation (OGD) back to levels seen 
in the normoxia controls.   
 The final experiments were performed to characterize the effects of the 
peripheral immune system on the brain over time and identify changes mediated 
by HUCBC and DTG.  Labeled splenocytes were found in spleen, blood, and 
thymus, but not in the brain in appreciable numbers at any timepoint.  IL10 and 
IFNγ levels were found to significantly increase by 96hours post MCAO.  This 
increase in IL10 and IFNγ expression was blocked HUCBC or DTG.   
The experiments described here have shed light on the molecular 
mechanisms of stroke injury and the relative targets that DTG and HUCBC 
therapies exploit.  These data suggest that the neuroprotection achieved by DTG 
or HUCBC is mediated by the ability of these treatments to modulate the 
peripheral immune systems response to injury. 
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Chapter 1 
 Background and Significance 
 
Clinical impact of stroke 
Each year, approximately 610,000 people suffer an initial stroke, and 
185,000 additional people have a recurrent attack. Every 40 seconds someone in 
the United States has a stroke making this disease a leading cause of death and 
disability in this country (Carandang et al. 2006). While the stroke death rates 
have decreased due to better treatment and hospital care, the lack of effective 
treatments to improve functional recovery has caused a concomitant increase in 
the number of people disabled by this disease.  The estimated direct and indirect 
cost of stroke in the U.S. is nearly $ 68.9 billion per year (Lloyd-Jones et al. 
2009), while the burden on families is unquantifiable and severe. 
Approximately 87% of stroke cases are due to an ischemic (embolic or 
thrombotic) stroke with the remainder being hemorrhagic in nature (Lloyd-Jones 
et al. 2009). Ischemic strokes can be further subcategorized into small vessel 
and large vessel strokes based on the size of the artery occluded.  Small vessel 
strokes, or lacunar strokes, occur when one of the small penetrating arteries 
which branch from larger vessels becomes occluded causing a small (<15mm) 
lesion in the subcortical regions of the brain (Norrving 2008).  This type of lesion 
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accounts for 25% of ischemic strokes and frequently acute stroke symptoms are 
not evident with the infarct only presenting as a small hole or “lacunae” upon 
necropsy.  When acute stroke symptoms do present, they normally present with 
one of five classical “lacunar syndromes”.   These include: pure motor 
stroke/hemiparesis, ataxic hemiparesis, dysarthria/clumsy hand, pure sensory 
stroke, and mixed sensorimotor stroke. These symptoms typically manifest when 
the lesion damages major subcortical structures such as the internal capsule, 
basis pontis, thalamus, or the pons.  As these strokes do not impact the cortex 
they do not present with pure cortical symptomology such as aphasia, neglect, 
and visual field defects (Fisher 1982).  Clinical prognosis in the near term for 
patients with lacunar infarcts is favorable as the acute (<30day) survival rate is 
~97%, and the chronic (1year and beyond) survival rate is 87% (Bejot et al. 2008; 
Sacco et al. 2006).  
Acute large vessel strokes typically occur when atherosclerotic plaques 
develop inside the large arteries feeding the brain causing them to become 
stenotic and easily occluded by blood clots.  These blood clots either break off of 
the plaque (thrombotic) or are generated elsewhere in the body (embolic). As 
these large vessels supply a greater portion of the blood supply to the brain the 
corresponding infarcts are larger and injure both cortical and subcortical 
structures.  This leads to pathologies which can include all lacunar symptoms in 
addition to cortical symptomology such as aphasia, neglect, and visual field 
defects. Clinical prognosis in the near term for patients with large vessel infarcts 
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is poorer than lacunar pathology as the acute (<30day) survival rate is 85%, and 
the chronic (1year and beyond) survival rate is 65-70% (Carandang et al. 2006). 
 Small vessel and large vessel strokes respond similarly to currently 
available interventions such as recombinant tissue plasminogen activator (rTPA) 
and aspirin suggesting a common pathological response to the injury (Norrving 
2008).  Functional MRI studies in large vessel strokes have determined that the 
infarct increases in size by 21% reaching a maximal value by 74 hrs and 
subsequently decreases in size during days 5-7 (Schwamm et al. 1998).  Similar 
effects on infarct size evolution have been observed in lacunar strokes further 
suggesting that a common response by the body to these ischemic injuries 
exists.  Furthermore similar kinetics have been observed rats following middle 
cerebral artery occlusion (MCAO) (Newcomb et al. 2006). 
 The body’s response to ischemic injury is multifaceted and changes over 
time.  Traditional imaging techniques in humans can provide details on the gross 
changes in infarct size, neuronal excitability, and cerebral blood flow. Although 
new ligands for positron emission tomography (PET) (Baron 2001) and functional 
magnetic resonance imaging (fMRI) techniques are beginning to shed light on 
the human response to ischemia (Baron 2002), animal models have been 
required to answer important questions about the cellular response to ischemia. 
 
Animal models of stroke 
 Rodent models of stroke have been critical to increasing our 
understanding of the pathology and progression of ischemia induced brain 
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lesions (Traystman 2003; Willing 2009).  Murine and rat models of stroke are 
commonly used and can be separated into two categories: global ischemia, in 
which total perfusion to the brain is blocked, and focal ischemia, in which 
perfusion of only part of the brain is inhibited. Focal ischemia includes 
transluminal middle cerebral artery occlusion in which an embolus is advanced 
into the MCA occluding blood flow, and distal middle cerebral artery occlusion in 
which the MCA is occluded by a clot which is either injected into the middle 
cerebral artery (Kaneko et al. 1985) or formed by the photolysis of a dye such as 
Rose Bengal (Markgraf et al. 1993).  Global ischemia is a model which more 
closely mimics the neuronal damage incurred following a heart attack, while focal 
ischemia more closely resembles an ischemic stroke.   
The distal middle cerebral artery occlusion technique lends itself to the 
study of thrombolytic therapy as the artery is occluded by a blood clot; however 
this technique is more traumatic to the animal as a craniotomy must be 
performed (Kaneko et al. 1985).  The transluminal middle cerebral artery 
occlusion technique is a commonly employed surgical stroke model.  Its 
advantages include the relative ease at which both permanent as well as 
transient ischemic events can be induced by merely leaving in or withdrawing the 
suture used to block the MCA, as well as reproducibility of the infarct size.  Due 
to the large size of the infarct produced, this model lends itself to investigations of 
neuroprotective treatments.  Furthermore, this stroke model closely mimics large 
vessel strokes which account for the majority of strokes in the human condition. 
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 Experimental rodent models of stroke have yielded a trove of information 
concerning stroke pathophysiology.  There has, however, been substantial 
difficulty translating therapeutic efficacy in rodents into improved clinical 
outcomes in stroke patients.  This is due in part to inherent differences between 
human patients and rodent models.  Humans are gyrencephalic organisms (have 
convoluted cortices) while rodents are lissencephalic (have smooth cortices).   
Humans also have a far greater proportion of white matter than rodents (Dewar 
et al. 1999; Hagberg et al. 2002). MRI imaging studies have demonstrated a 
correlation between lesions which impact the descending motor tracts, which are 
composed of white matter, and poorer function outcome in patients (Dawes et al. 
2008; Pineiro et al. 2000).  White matter dysfunction in ischemic injury is 
understudied compared to neuron rich grey matter and is a likely source of the 
disparity seen between infarct volume reductions in rodents and functional 
improvements in patients.   
Another confound between animal models and the human condition is in 
the age and condition of the subject.  Stroke patients are typically elderly and 
often present with underlying disease states such as high blood pressure, 
diabetes, atherosclerosis, and heart disease.  Animal models, on the other hand, 
typically utilize healthy adolescent male subjects.   Advanced age and underlying 
pathology can reduce the efficacy in humans of treatments which were protective 
in rat models.   
Perhaps the most important source of discrepancy between animal and 
human models of stroke lies not in the model itself but in the experimental design 
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utilizing the model.  Many researchers neglect to take into consideration the 
human conditions when designing in vivo experiments.  Administration of 
experimental neuroprotectants at the time of or prior to the onset of ischemia 
may be useful for understanding disease pathology but are impractical for use in 
the clinic. Patients typically arrive at the ER many hours after stroke, and are in a 
condition not modeled by the treatment paradigm.  Indeed many of the preclinical 
studies targeting excitotoxicity such as NMDA antagonism and calcium channel 
blockade succumbed to this flaw and the treatments were ineffective clinically. 
 
Failed therapies for stroke 
 Attempts to develop neuroprotective treatments for stroke have yielded 
disappointing results thus far.  Therapeutic interventions can be grouped into two 
broad categories: therapies targeting neurons and the early processes implicated 
in their demise, and therapies which target the delayed glial/immune response to 
stroke.  The vast majority of trials to date have focused on reducing the buildup 
of intracellular calcium, neuronal firing, and free radicals.  These therapies were 
developed in order to combat a phenomenon called excitotoxicity which is 
thought to damage neurons (Dirnagl et al. 1999).  Neuronal damage in this model 
is caused by the overactivation of NMDA channels on penumbral neurons due to 
high levels of glutamate and aspartate released from the ischemic core.  This 
increased NMDA receptor activation causes calcium to enter the cell where it can 
activate proapoptotic signaling cascades, cause free radical buildup, and trigger 
neuronal death (Dirnagl et al. 1999).  Multiple steps in this excitotoxic process 
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have been targeted for intervention such as NMDA receptor antagonism 
(Selfotel) (Davis et al. 2000), AMPA receptor antagonism (ZK200775) (Elting et 
al. 2002), calcium channel blockade (Flunarizine) (Limburg and Hijdra 1990), 
GABA activation (Clomethiazole) (Lyden et al. 2001), sodium channel blockade 
(fosphenytoin), potassium channel opening (BMS-204352), and free radical 
scavengers (Lubeluzole) (Diener et al. 2000).  While these therapies were 
effective in preclinical animal studies, none showed significant improvement 
clinically.  Some of the reasons include a short therapeutic time windows (<1 hr) 
for efficacy, and undesirable side effects such as hallucination and psychosis 
(NMDA receptor antagonists) (Davis et al. 2000) and severe reductions in blood 
pressure (calcium channel blockers) (Horn et al. 2001). 
Trials which target the glial/immune response to stroke have also been 
unsuccessful.  The earliest of these trials involved the use of high dose 
dexamethasone to suppress the inflammatory response following stroke (Mulley 
et al. 1978).  Later trials have focused on preventing immune cell infiltration of 
the infarct by administering antibodies or other recombinant proteins to bind 
adhesion molecules and prevent immune cell infiltration following stroke (1999; 
2001; Lees et al. 2003).  All of these trials failed to show therapeutic efficacy in 
clinical trials and all but UK-279276 (neutrophil inhibitory factor) significantly 
increased post stroke mortality as well. 
The failures presented here suggest that our knowledge of post-ischemic 
pathology is incomplete.  Therefore it is imperative that novel therapeutic 
strategies be developed, not only to improve the clinical setting, but also to 
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improve the understanding of the underlying mechanisms of this disease.  To 
develop these therapies the underlying processes which occur following ischemia 
must be elucidated. 
 
The local response to ischemia 
  Rapidly following the obstruction of blood flow to the brain the tissue 
parenchyma undergoes significant changes.  The area of brain tissue that 
receives blood supply primarily from the occluded vessel and has a greater than 
75% loss in perfusion is called the core of the infarction.  Neurons in the core of 
the infarct are under the greatest metabolic stress and are the least likely to be 
responsive to neuroprotective treatments (Lipton 1999).  The area surrounding 
the core of the infarction which receives partial blood perfusion from collateral 
blood vessels is known as the penumbra.  Cells in the penumbra while under 
some metabolic demand are further stressed by stroke associated phenomena 
such as anoxic depolarization and inflammation which can cause their 
destruction at delayed timepoints.  The penumbra is the primary target for 
neuroprotective therapies since it accounts for a significant area of the infarct and 
does not die as quickly as the core.   
 When the artery supplying blood flow to brain tissue becomes obstructed, 
loss of ATP necessary for the maintenance of ionic homeostasis, leads to rapid 
calcium accumulation in ischemic neurons (Lipton 1999).  This process leads to 
increased in neuronal firing causing a phenomenon known as anoxic 
depolarization.  Anoxic depolarization in non-ischemic brain does not cause 
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neuronal loss, and when induced 3 days prior to ischemia can cause 
neuroprotection via ischemic preconditioning mechanisms (Obrenovitch 2008).  
In ischemic brain, however, the increased neuronal firing exacerbates the 
metabolic demand and further decreases energy stores in ischemic neurons 
leading to their compromise (Takano et al. 1996).  The increases in intracellular 
calcium levels induce intracellular phospholipases, proteases, and 
endonucleases lead to the functional compromise of the neuron. This results in 
the production of inflammatory lipid peroxidation products such as prostanoids 
which can exacerbate membrane permeability and lead to cytotoxic edema 
(Dirnagl et al. 1999).  This leakiness of the neuronal plasma membrane also 
results in the release of ATP into the extracellular space. This release of ATP 
leads to the early activation of the resident microglia and astrocytes inducing the 
acute inflammatory response.  
 
Endogenous microglial activation during the early inflammatory response 
 Microglia are the resident macrophages of the brain, which under normal 
conditions are kept in a quiescent state. Resting microglia exhibit a ramified 
morphology in vivo characterized by fine processes expressing chemosensitive 
receptors (Streit et al. 2004). In an uninjured brain these cells are involved 
essential functions such as synaptic pruning, debris removal, defense against 
infection, and neurotrophic support (Streit et al. 2005).  
Studies using GFP-labeled microglia in vivo demonstrated that microglial 
processes are highly mobile and quickly move towards ATP released by injured 
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neurons (Davalos et al. 2005; Haynes et al. 2006). Microglia can then assist the 
damaged neuron by sequestering glutamate (van Landeghem et al. 2001) in 
addition to releasing neurotrophins such as BDNF (Coull et al. 2005) and TGFβ 
(da Cunha et al. 1997; Lehrmann et al. 1998).  In ischemia where the number of 
injured neurons is large the microglia will then withdraw their processes, 
assuming an amoeboid “activated” phenotype (see Garden et al (Garden and 
Moller 2006) for review), and can secrete cytotoxins such as nitric oxide, reactive 
oxygen species, and prostaniods (Gibson et al. 2005).  These cells can also 
promote the inflammatory response by secreting pro-inflammatory cytokines 
such as IL1β and TNFα (Allan and Rothwell 2001; Dirnagl et al. 1999).  Whether 
this causes neuronal death directly however is uncertain as ablation of microglia 
exacerbates ischemic injury (Lalancette-Hebert et al. 2007). 
 This release of inflammatory cytokines was originally thought to 
exacerbate ischemia induced injury based on in vitro studies where direct 
application of these IL1β and TNFα (Jara et al. 2007; Thornton et al. 2006) killed 
cultured neurons, and in vivo studies where neutralization of these cytokines by 
endogenous receptor antagonist (Relton et al. 1996) or soluble receptor (IL1β 
and TNFα  respectively) reduced infarct volumes.  Whether these effects are due 
to direct neuronal toxicity are unclear as IL1β amplifies the initial immune 
infiltration by stimulating microglia and astrocytes to produce MMP9.  In vivo 
studies using TNF receptor knockout mice have demonstrated that microglial 
derived TNFα is neuroprotective via activation of the of the p55 subunit of the 
TNF receptor (Lambertsen et al. 2009).  Furthermore ablation of microglia 
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exacerbates ischemic injury (Lalancette-Hebert et al. 2007).  In early ischemic 
injury, the release of IL1β, TNFα, and IL6 by microglia is extremely important in 
the transition from a local immune response to a global immune/stress response 
(Zheng and Yenari 2004). 
 
Activation of the neuro-immune and hypothalamic pituitary adrenal axes 
 Local inflammation has both beneficial and deleterious effects on ischemic 
lesions. When the local inflammation activates the peripheral immune system, 
however, a much larger inflammatory response is elicited causing collateral 
destruction of the peri-infarct regions (Offner et al. 2006).  Therefore, the 
peripheral inflammatory response to brain injury is tightly regulated.  The brain 
communicates with the immune system largely via direct innervation of lymphoid 
tissues and humeral control provided by the hypothalamic-pituitary-adrenal axis 
(HPA axis) (Chrousos 1995).  Inflammatory cytokines IL1β, TNFα, and IL6 
released in response to brain injury stimulate centers in the locus ceruleus to 
induce neural sympathetic activation, as well as cause the release of CRH in the 
hypothalamus (Chrousos 1992).  IL1β and TNFα stimulate the production of IL6 
which in turn inhibits their production.  IL6 acts synergistically with glucocorticoids 
to induce the release of acute phase reactants from the liver including C-reactive 
protein.  C-reactive protein and IL6 are elevated in the serum of patients with 
ischemic stroke and are correlated with poorer outcomes.   
Stimulation of either the locus ceruleus or the HPA axis activates the other 
based on neural crosslinks between the lateral paraventricular nucleus and the 
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locus ceruleus (Saper et al. 1976).  Once these systems are activated, the 
resulting release of epinephrine from the adrenal glands in addition to the direct 
secretion of norepinephrine into the lymphoid organs by sympathetic nerve fibers 
results in a “sympathetic storm” (Chamorro et al. 2007).  The increase in 
circulating catecholamines in addition to increased plasma cortisol 
concentrations suppress immune cell function.  This acute stress response alters 
the morphology of the two peripheral lymphoid organs known to be involved in 
the progression of stroke: the thymus and the spleen (Elenkov et al. 2000).   
 The thymus and the spleen are densely innervated by noradrenergic 
nerve terminals (Anagnostou et al. 2007), and upon induction of CNS ischemia 
become reduced in size (Offner et al. 2006; Vendrame et al. 2006).  Multiple 
groups have associated this decrease in thymus and spleen size with profound 
leucopenia and an increased susceptibility to infection based a lack of IFNγ 
producing T-cells (Prass et al. 2003; Yilmaz et al. 2006).  This 
immunosuppression, while likely helpful at reducing permanent brain injury, can 
be reversed by administration of beta-adrenergic blockers such as propranolol 
(Meisel et al. 2005; Prass et al. 2006).  The Offner group postulated that the 
decrease in spleen and thymus size was due to mass apoptotic cell death in 
these organs based on TUNEL immunoreactivity (Offner et al. 2006).  Recent 
work in our lab has demonstrated that the spleen shrinkage is due to activation of 
alpha1 adrenergic receptors located on the smooth muscle capsule and this 
shrinkage can be blocked by prophylactic administration of prazosin, an alpha1 
receptor antagonist.  
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Human blood samples taken during the PANTHERIS trial (Klehmet et al. 
2009) and in other clinical stroke settings (Urra et al. 2009), confirmed the 
increased catecholamine levels in stroke patients in addition to the leucopenia .  
It is still unclear whether increased susceptibility to infection in the clinical setting 
is a direct product of this immunosuppression, or a product of stroke induced 
complications.  These complications include dysphasia, which is known to 
increase pneumonia incidence, and the need for a urinary catheter, which is 
associated with increased urinary tract infections (UTIs).  Pneumonia and UTIs 
are common stroke associated nosocomial infections and are the leading causes 
of delayed (>5 day) stroke mortality (Aslanyan et al. 2004).  
 
The role of the peripheral lymphoid organs in stroke 
The induction of such profound immunosuppression indicates that the 
peripheral lymphoid organs can exacerbate ischemic injury.  The spleen in 
particular plays a critical role in the response to ischemic injury.  Cell tracking 
studies of intravenously (i.v.) injected of human umbilical cord blood cells 
(HUCBC) into rats receiving MCAO identified the spleen and the infarct as the 
primary targets of this therapy (Vendrame et al. 2004a).  Studies comparing i.v. 
injection to striatal injection of HUCBC showed that i.v. injection was superior 
suggesting that the splenic actions of these cells were important for the 
therapeutic benefit of this treatment (Willing et al. 2003).  Splenectomy 
significantly reduces ischemic injury in multiple organ systems including liver 
(Okuaki et al. 1996), GI tract (Savas et al. 2003), and kidney (Jiang et al. 2007).  
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Recent results in our lab show that splenectomy prior to stroke reduces infarct 
volume by 80% (Ajmo et al. 2008); similar to levels of protection seen in HUCBC 
therapies (Vendrame et al. 2004b).  This significant protective effect in multiple 
tissue types indicates that the spleen contributes to ischemic injury in a tissue 
type independent manner, and this response likely is responsible for infarct 
expansion and degeneration of the penumbra.   
 
The peripheral leukocyte response to ischemia 
 Upon induction of ischemia, endothelial cells in the infarct begin the 
process of recruiting peripheral leukocytes into the damaged parenchyma by 
upregulating ICAM1 and ICAM2 (Lindsberg et al. 1996; Wang et al. 1994). The 
first leukocyte subtype to infiltrate the brain is neutrophils, a small 
polymorphonuclear cell which begins to adhere to the endothelium between 1 
and 6 hours following ischemia onset and invade the infarct beginning 6 hours 
after adherence (Kochanek and Hallenbeck 1992).  These cells express selectins 
and integrins which enable them to extravate between the endothelial cells and 
begin degrading the basal lamina through the secretion of matrix 
metalloproteinase and other proteases (Jean et al. 1998; Matsuo et al. 1994).  
These proteases not only further weaken the blood brain barrier but also 
contribute to the ensuing inflammation by activating chemokines such as MCP-1 
and SDF-1a (Overall et al. 2002) along with proinflammatory cytokines such as 
IL1β (Schonbeck et al. 1998) and TNFα (Gearing et al. 1994).  These 
chemoattractants further serve to recruit peripheral leukocytes such as 
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macrophages, T and B lymphocytes, and dendritic cells to the infarcted tissue.  
Once within the parenchyma, neutrophils release reactive oxygen and nitrogen 
species in addition to various enzymes such as myeloperoxidase and elastase 
which are normally sequestered in their cytoplasmic granules (Jean et al. 1998).  
These observations of potential neurodestructive capabilities of 
neutrophils, however, must be weighed against the results from clinical trials 
which show no added clinical benefit to blocking neutrophil migration. These 
studies used several differing molecular targets to achieve this such as: 
neutrophil inhibitory factor (a recombinant glycoprotein with selective binding to 
the CD11b integrin of MAC-1 (CD11b/CD18)), inhibition of leukocyte adhesion by 
antibodies against ICAM (Enlimomab Acute Stroke Trial), or CD18 (HU23F2G 
Anti-Adhesion to Limit Cytotoxic Injury trial).  The antibody studies resulted in 
increased morbidity and mortality and both trials using this rationale were 
discontinued due to safety concerns.   
Much of the toxicity attributed to neutrophils was based on the activity of 
the enzyme myeloperoxidase which produces highly reactive oxygen species 
and is correlated with both increased infarct volume and poorer outcome after 
stroke (Kitamura et al. 1997).  Myeloperoxidase is expressed not only by 
neutrophils, but by all cells of myeloid lineage including macrophages (Lagasse 
and Weissman 1994).  In vivo imaging of myeloperoxidase activity showed peak 
activation 3 days after MCAO, a timepoint which is well after the initial influx of 
neutrophils and correlates with peak macrophage aggregation (Weston et al. 
2007).  There is evidence in the literature that macrophages phagocytose 
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neutrophils in the ischemic infarct, with 50% of neutrophils in the infarct being 
engulfed three days after MCAO (Meszaros et al. 1999; Weston et al. 2007).  
This engulfment is one of the primary mechanisms by resolution of neutrophil 
based inflammation, with macrophages preferentially clearing aging neutrophils 
first (Lagasse and Weissman 1994). 
 Macrophage accumulation following ischemia is highly correlated with the 
production of the chemokine MCP-1 (Wang et al. 1995).  This chemokine is 
produced and secreted as a protein precursor by astrocytes and neurons (Che et 
al. 2001; Gourmala et al. 1997).  This chemokine is activated and released by 
proteases such as plasmin (Sheehan et al. 2007) and is detected beginning at 6 
hours following transient ischemia (Yamagami et al. 1999).  This timepoint 
correlates with neutrophil infiltration and is likely related to production of MMPs 
by these cells.  MCP-1 expression increases and reaches peak levels between 2 
and three days following MCAO which correlates with the influx of macrophages 
to the infarct (Wang et al. 1995).  MCP-1 also induces the expression of ICAM-1 
mRNA in kidney models (Giunti et al. 2006; Viedt et al. 2002) and likely further 
increases invasion of the brain parenchyma by peripheral immune cells. 
Ameboid macrophages are the most abundant immune cells in the infarct 
following MCAO (Stoll et al. 1998).  Whether these cells are microglia which have 
transformed into an amoeboid phenotype or are infiltrating monocytes is 
impossible to determine immunohistochemically or morphologically.  Studies in 
which peripheral macrophages are labeled with iron particles and tracked 
following photochemically induced MCAO suggest that peripheral macrophage 
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recruitment is a delayed phenomenon which peaks at 5 days following MCAO. 
(Kleinschnitz et al. 2003)  These finding suggest that the macrophages which are 
observed at 3 days following MCAO are microglial in origin. Histochemical 
studies following ischemia, however, do suggest that a population of CD8+ 
macrophages do infiltrate the CNS within 48 hours following ischemia, though 
their function is not known (Jander et al. 1998).  
Regardless of their origin, amoeboid macrophage levels peak by 3 days 
following MCAO and remain elevated for weeks following insult.  These cells are 
involved in tissue destruction, turnover of extracellular matrix, removal of cell 
debris, and wound healing (Schilling et al. 2005).  Depletion of peripheral 
macrophages using clodronate liposomes has no effect on infarct volume 
suggesting that these cells do not directly induce ischemic damage (Schroeter et 
al. 1997). Sheets of “foamy” macrophages have been described in infarcts of 
stroke patient’s brains at delayed timepoints further confirming the phagocytic 
and tissue removal functions of these cells (Petroff et al. 1992). Macrophage 
depletion impairs remyelination after injury (Kotter et al. 2001), demonstrating a 
complex role in infarct development and resolution. 
While cells of the innate immune system are the most numerous found in 
the infarct, cells of the adaptive immune system play an important role in stroke 
pathology. T and B lymphocytes infiltrate the infarct along with neutrophils and 
macrophages and contribute to the inflammation and tissue destruction that 
occurs there.   Under normal conditions the brain is considered an immune 
privileged organ.  When T-cells enter the parenchyma following ischemia, they 
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are exposed to new antigens such as myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG) which they have not been exposed to during 
the self selection process.  Experiments in which mice were tolerized to these 
proteins prior to MCAO showed a significant reduction in infarct volume 
demonstrating that adaptive immunity plays a significant part in the post stroke 
inflammatory response (Frenkel et al. 2003; Gee et al. 2008).  Severe combined 
immunodeficient (SCID) mice and recombinase activating gene 1 (Rag-/-) 
knockout mice, which lack functional T-and B- lymphocytes, had significantly 
smaller infarcts when compared to their wild type litter mates following transient 
MCAO (Yilmaz et al. 2006). Further studies in which mice which lacked CD4+ 
and CD8+ T-lymphocytes were subjected to transient MCAO showed that these 
T-lymphocyte subtypes are important for the induction of tissue damage following 
ischemia (Yilmaz et al. 2006).  
B-lymphocytes are recruited to the brain following MCAO.  Their role once 
there may be a protective one, as mice which lack B-lymphocytes did not have 
reduced infarct volumes suggesting that these cells may not directly participate in 
the acute phase destruction of tissue (Yilmaz et al. 2006).  Additionally in human 
patients, lower B-cell counts, but not other leukocyte subpopulations, in the blood 
correlated with adverse outcomes upon admission and at 2 days after stroke 
implying a protective effect of these cells (Urra et al. 2009).  As interactions 
between B-cells and antigen presenting cells elicit an anti-inflammatory humeral 
response, reduced numbers of B-cells may correlate with increased inflammation 
and increased brain damage (Harling-Berg et al. 1999).  Alternatively increased 
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brain damage may induce a stronger stress response from the HPA axis causing 
increased cortisol levels increasing β2-adrenergic receptors which can result in 
increased apoptosis of B-cells in response to catecholamines.  
 
Current therapies for stroke 
While much has been learned about the mechanisms by which stroke 
damage occurs, the design of new therapeutics for ischemic injury has been 
fraught with failure.  The only currently available interventions for stroke sufferers 
are thrombolytics such as rTPA and mechanical clot removal (Marler and 
Goldstein 2003).  These therapies are aimed solely at restoring blood flow to the 
infarcted tissue, have no direct neuroprotective properties, and must be 
administered at similar timepoints.  In order to provide benefit these therapies 
must be administered at a very early timepoint prior to the induction of the 
inflammatory response.  The numbers of patients, who arrive at the hospital, 
receive a CT scan to rule out hemorrhagic stroke, and be administered therapy 
within the 3-6 hour time window are small, representing only 3-5% of stroke 
sufferers (Marler and Goldstein 2003).  
 Tissue plasminogen activator is a serine protease produced by 
macrophages and endothelial cells, which converts plasminogen to plasmin, a 
fibrin cleaving enzyme (Teesalu et al. 2002).  Plasminogen, a zymogen secreted 
by the liver, binds fibrin and is incorporated into blood clots.  Fibrin is a protein 
found in blood clots which is composed of chains of fibrin monomers linked 
through the action of coagulation factor III.  Once plasminogen is converted to 
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plasmin, it cleaves fibrin, releasing soluble fragments and exposing lysine 
residues which the plasmin binds to prior to cleaving again. 
Of those patients whom are candidates for rTPA, only 13% had an 
improved outcome compared to placebo (Albers et al. 2004).  This benefit must 
also be weighed against the significantly increased risk for bleeding, a process 
called hemorrhagic transformation (Toni et al. 1996).  In this process, rTPA can 
activate proMMP9 present in neutrophils granules leading to further degradation 
of the basal lamina and increased risk for bleeding (Cuadrado et al. 2008).  
Mechanical clot disruption is a nonenzymatic method of restoring blood flow by 
physically removing a clot.  In this method, a catheter is introduced into the 
blocked artery and a device (frequently a coil) is inserted into the clot, the 
catheter is then removed pulling the clot free, and allowing recanalization (Noser 
et al. 2005).  This technique can be used in conjunction with rTPA and has 
shown promising results in phase 2 clinical trials (Kim et al. 2006).  Phase three 
clinical trials such as the IMSIII trial are underway and should shed light on the 
therapeutic efficacy of this technique. 
 
Therapeutic targets for stroke at delayed timepoints 
 Until recently it was believed that neurons died very rapidly following 
stroke onset by these excitotoxic mechanisms.  This was based on the 
observation of neurons which had become pyknotic and expressed various 
markers for apoptosis such as Annexin V, cleaved caspase 3, and TUNEL stains.  
This belief was challenged on observations that HUCBC could reverse these 
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apoptosis markers resulting in a 50-70% reduction in infarct volume when 
administered up to 48 hours after undergoing permanent MCAO (Vendrame et al. 
2004a).  HUCBC are the mononuclear fraction of cells isolated from umbilical 
cord blood collected after birth.  This cell population includes approximately 1% 
CD34+ stem cells with the remainder being lymphocytes at varying stages of 
development.  HUCBC administration is associated with profound 
neuroprotective and anti-inflammatory effects when administered in animal 
models of a variety of disease states such as ALS (Garbuzova-Davis et al. 2003), 
Alzheimer’s disease (Nikolic et al. 2008), Parkinson’s disease (Ende and Chen 
2002), spinal crush injury (Saporta et al. 2003), and stroke (Newcomb et al. 
2006; Vendrame et al. 2004a).  While this therapeutic does have a stem cell 
component, cell tracking studies demonstrated that very few of these cells 
actually implanted into the damaged tissue suggesting that this is not a cell 
replacement therapy (Vendrame et al. 2004a). 
 Further studies in our lab have identified the sigma receptor agonist 1, 3-
di-o-tolylguanidine (DTG) as a therapy which substantially reduces infarct volume 
when administered 24 hours following MCAO (Ajmo Jr et al. 2006).  The 
identification of a second unrelated therapeutic which is neuroprotective at 
delayed timepoints suggests that there is an underlying mechanism which can be 
harnessed to provide neuroprotection at a time when a majority of stroke patients 
can be seen and treated.  Furthermore, this suggests that excitotoxicity and 
anoxic depolarization are not as damaging as once thought.  This finding has 
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important implications with respect to the treatment of hypoxic ischemic injury in 
other disease paradigms. 
 Other treatments which suppress infarct volumes at delayed timepoints 
include ethyl pyruvate (Yu et al. 2005) and granulocyte colony stimulating factor 
(Sehara et al. 2007),.  These treatments also have potent anti-inflammatory 
properties and show functional recovery in addition to reduced infarct volumes. 
 
Sigma receptor agonists as a therapy for stroke 
Sigma receptors are membrane associated proteins found widely 
distributed in the mammalian brain, peripheral neurons, and visceral organs. 
These receptors were first identified by Martin et al., and have since been 
classified into two types on the basis of pharmacology, sigma-1 and sigma-2 
(Quirion et al. 1992).  Both subtypes have high to moderate affinity for 
antipsychotics, such as haloperidol, and guanidines. Sigma-1 receptors have a 
higher affinity for (+)-benzomorphans, such as (+)-pentazocine, than sigma-2 
receptors, whereas sigma-2 receptors have higher affinity for ibogaine and its 
congeners. Thus far, only the sigma-1 receptor has been cloned, and this protein 
is detected on the membranes of the endoplasmic reticulum and influences 
calcium release from this organelle (Hayashi and Su 2001; Seth et al. 1998). 
 The sigma-1 receptor, with two putative transmembrane domains, bears 
no resemblance to any other known mammalian protein. While the endogenous 
ligand for sigma receptors has not been clearly identified, various candidates 
have been suggested. N, N-dimethyltryptamine has been recently described as a 
23 
nonsteriodal endogenous ligand for the sigma-1 receptor (Fontanilla et al. 2009), 
perhaps explaining the significant anti-anxiolytic properties of sigma receptor 
agonists. Neurosteroids like progesterone were also shown to bind sigma 
receptors with high affinity, leading to the speculation that some of the 
physiological actions of progesterone are mediated by sigma receptors (Su et al. 
1990). Other neurosteroids, including pregnenolone and 
dehydroepiandrosterone, have high affinity for sigma receptors.  Given the 
neuroprotective properties of neurosteroids and their abundance in the cortex, 
these sigma ligands would be obvious candidates for the possible endogenous 
neuroprotection by sigma receptors reported here.   
 Numerous in vivo studies have demonstrated a protective role for sigma 
receptors following ischemia.  Rats subjected to transient MCAO had reduced 
infarct volume when various sigma ligands such as dimemorphan (Shen et al. 
2008), (+)pentazosin (Takahashi et al. 1997), and 4-phenyl-1-(4-phenylbutyl) 
piperidine (PPBP) (Takahashi et al. 1996) were administered during reperfusion.  
Inhibition of various components of the early response to stroke such as NMDA 
receptor activation, neuronal nitric oxide synthesis, and inducible nitric oxide 
synthesis have been postulated to mediate this neuroprotection.  Activation of 
sigma receptors at 24 hours in the permanent MCAO model by DTG is also 
neuroprotective (Ajmo et al. 2006), though at this timepoint it is likely that 
modulation of the immune system plays a larger role in this effect. 
 The neuroprotective properties of sigma receptors in vitro have been 
ascribed to their ability to stabilize intracellular calcium levels due to NMDA 
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receptor activation and block anoxic depolarization.  Subsequent studies 
demonstrate that sigma receptor activation blocks ischemia induced calcium 
increases by suppressing calcium influx through multiple pathways (Katnik et al. 
2006).  Recent work demonstrates that sigma receptor activation suppresses 
acid sensing ion channel function (Herrera et al. 2008).  This family of channels 
induces calcium influx in the presence of high levels of extracellular protons 
generated by glycolysis and excessive neurotransmission (Xiong et al. 2007).  
Pharmacological inhibition of this ion channel is protective when administered 
within 5hrs of MCAO (Xiong et al. 2008).  It remains to be determined whether 
the benefit seen in vivo; due to these effects at the levels of the neuron or due to 
the effects of sigma receptor activation on immune system function, or both. 
 A role of sigma receptors in the immune system was first proposed by T.P. 
Su et al. based on their observation that lymphoid tissues express sigma binding 
sites (Su et al. 1988).  Subsequent studies have shown that sigma receptor 
activation can regulate the function of various cells of the immune system.  
Selective sigma-1 receptor activation is associated with reduced leukocyte 
invasiveness and decreased levels of inflammatory cytokines in vivo (Zhu et al. 
2003).  Sigma ligands such as (+) pentazocine, haloperidol, and DTG suppress 
in vitro murine splenocyte natural killer activity and polyclonal immunoglobulin 
production following mitogen stimulation (Carr et al. 1991).  Systemic 
administration of the sigma ligand, SR 31747A, inhibits the secretion of TNF-α 
and IFNγ evoked by injection of LPS in rats (Bourrie et al. 2002).  This sigma 
ligand has also been shown to inhibit NO production in LPS-activated 
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macrophages (Gannon et al. 2001). In the CNS, sigma-1 receptors are 
expressed in microglia (Gekker et al. 2006), and our laboratory has shown that 
sigma receptor activation is associated with decreased reactive gliosis following 
stroke injury in rats (Ajmo et al. 2006). The immunosuppressive effects of 
cocaine have been attributed to sigma receptor activation via heightened 
expression of TGF-β (Gekker et al. 2006), an anti-inflammatory cytokine altered 
following ischemia. 
 
Determining the impact of DTG on the post ischemic inflammatory 
response-the current project 
 While sigma ligands have been studied in the treatment of ischemia, 
previous projects have focused on reperfusion injury, neuronal calcium 
dysregulation, and/or anoxic depolarization.  While these studies are useful for 
understanding sigma receptor biology during early ischemia, they have very little 
relevance to the clinical condition.  The major caveat with attempting to intervene 
in these pathological systems is that they typically occur at timepoints well before 
patients are seen for treatment.  A major finding in our lab, centers around the 
ability of DTG to impart significant neuroprotection when therapy is administered 
24 hours following permanent MCAO.  The only other treatments which have 
efficacy at such delayed timepoints such as minocycline and HUCBC have 
immunomodulatory properties.   
 Microglia are the endogenous immune cells of the brain and are 
intrinsically linked to induction, development, and maintenance of the post 
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ischemic inflammatory response.  The first set of experiments described here 
were undertaken to test the following hypotheses: (1) sigma receptor 
activation suppresses microglial activation in culture, and (2) suppression 
of intracellular calcium is the process which sigma receptor activation 
targets to suppress microglial activation. 
 Dissociated microglial cultures are a good model for elucidating 
intracellular signaling cascades which occur during activation.  The relevance of 
this model to ischemic injury however is low.  The organotypic slice culture model 
has many advantages over dissociated cell culture.  Principal among these is 
that all cell types found in brain parenchyma are present and many of their 
functional connections are maintained.  When these cultures are subjected to 
ischemic conditions, microglia are activated in conditions similar to those found in 
vivo.  Furthermore as sigma receptor activation modulates microglial and 
peripheral leukocyte activation this model allows the exploration of the effect of 
sigma receptor activation without the input of the peripheral immune system.  
The second set of experiments presented here explores the following 
hypotheses: (1) that ischemia results in robust neurodegeneration 
resulting in microglial activation as measured by nitric oxide production, 
and (2) sigma receptor mediated suppression of microglial activation 
confers neuroprotection. 
 In vivo, peripheral immune cells infiltrate the infarct prior to the 24 hour 
timepoint at which DTG is efficacious.  Peripheral T-lymphocytes in particular are 
involved in stroke induced neurodegeneration, likely through interactions with 
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antigen presenting cells like macrophages/microglia residing in the infarct.  One 
source of T-lymphocytes which contributes to ischemic neurodegeneration is the 
spleen.  Sigma receptor activation can modulate T-cell antigen presenting cell 
interaction by upregulating the production of anti-inflammatory cytokines IL10 
and TGFβ in T-cells and microglia respectively decreasing peripheral 
inflammation.  Therefore, the third set of experiments presented here will 
test the hypothesis that: (1) splenic peripheral immune cells infiltrate the 
infarct following MCAO, and (2) DTG treatment reduces the prevelance of 
these cells in the infarct 
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Abstract 
During brain injury, microglia become activated and migrate to areas of 
degenerating neurons. These microglia, release pro-inflammatory cytokines and 
reactive oxygen species causing additional neuronal death.  Microglia express 
high levels of sigma receptors, however, the function of these receptors in 
microglia and how they may affect the activation of these cells remain poorly 
understood.  Using primary rat microglial cultures, it was found that sigma 
receptor activation suppresses the ability of microglia to rearrange their actin 
cytoskeleton, migrate, and release cytokines in response to the activators 
adenosine triphosphate (ATP), monocyte chemoattractant protein 1 (MCP-1), 
and lipopolysaccharide (LPS).  Next, the role of sigma receptors was explored in 
the regulation of calcium signalling during microglial activation.  Calcium 
fluorometry experiments in vitro show that stimulation of sigma receptors 
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suppressed both transient and sustained intracellular calcium elevations 
associated with the microglial response to these activators. Further experiments 
showed that sigma receptors suppress microglial activation by interfering with 
increases in intracellular calcium.  In addition, sigma receptor activation also 
prevented membrane ruffling in a calcium-independent manner, indicating that 
sigma receptors regulate the function of microglia via multiple mechanisms. 
 
 
Introduction 
A principal aspect of the central nervous system (CNS) immune response 
to injury is the recruitment and activation of endogenous microglia.  Microglia are 
the resident macrophages of the brain, which are kept in a quiescent ramified 
state under normal conditions. These cells respond to substances released by 
damaged neurons or invading pathogens by migrating to the site of injury, 
phagocytosing debris, and releasing pro-inflammatory mediators, such as 
cytokines and reactive oxygen species (Streit et al. 2004).  In several 
pathological states of the CNS, this response contributes to the destruction of 
compromised neurons enhancing neurodegeneration (Dheen et al. 2007; Rogove 
et al. 2002; Streit et al. 2004).  Current research suggests that the inflammatory 
response after brain injury can be inhibited by sigma receptor activation (Ajmo et 
al. 2006).  These receptors are neuroprotective in several animal models of 
stroke injury (Ajmo et al. 2006; Harukuni et al. 1998), and represent a putative 
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target for neuroprotection at delayed time points (≤ 24 hrs) following stroke onset 
(Ajmo et al. 2006). 
Sigma receptors are membrane associated proteins found widely 
distributed in the mammalian brain, peripheral neurons, and visceral organs. Two 
subtypes of sigma receptors, sigma-1 and sigma-2, have been identified based 
on their pharmacological profiles (Quirion et al. 1992).  Thus far, only the sigma-1 
receptor has been cloned (Seth et al. 1998), and this protein is detected on the 
membranes of the endoplasmic reticulum and influences calcium release from 
this organelle (Hayashi and Su 2001).   
 Sigma receptors were  identified in the immune system using radioligand 
binding studies in lymphoid tissues (Su et al. 1990).  Selective sigma-1 receptor 
activation is associated with reduced leukocyte invasiveness and decreased 
levels of inflammatory cytokines in vivo (Zhu et al. 2003).  Sigma ligands such as 
(+) pentazocine, haloperidol, and 1,3-di-o-tolylguanidine (DTG) were found to 
suppress murine splenocyte activity and polyclonal immunoglobulin production 
following mitogen stimulation in vitro (Carr et al. 1991).  Systemic administration 
of the sigma ligand, SR 31747A, inhibits the secretion of tumor necrosis factor-α 
(TNF-α) and interferon gamma (IFN-γ) evoked by injection of LPS in rats (Bourrie 
et al. 2002).  This sigma ligand has also been shown to inhibit nitric oxide (NO) 
production in LPS-activated macrophages (Gannon et al. 2001). In the CNS, 
sigma-1 receptors are expressed in microglia (Gekker et al. 2006), and our 
laboratory has shown that sigma receptor activation is associated with decreased 
reactive gliosis following stroke injury in rats (Ajmo et al. 2006).  
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This study investigated sigma receptor modulation of microglial activation. 
Specifically, experiments were done to characterize the effects of sigma receptor 
activation on morphological, migratory, and inflammatory responses of microglia 
and to determine the role of intracellular calcium concentration on the regulation 
of these processes. It was found that sigma receptor activation suppressed the 
morphological, migratory, and inflammatory aspects of microglial activation.  
Further studies revealed that sigma receptor activation regulates these 
processes by suppressing calcium increases.  However, calcium-independent 
regulation of microglia activation by sigma receptors was also noted, indicating 
that sigma receptors regulate these cells by affecting various signaling pathways. 
 
Materials and Methods 
 
Primary Cultures of Microglia   
Primary cultures of microglia were prepared from postnatal (2 day) 
Sprague-Dawley rat pups using a protocol modified from Gottschall et al 
(Gottschall et al. 1995). Briefly, pups were decapitated, cortices dissected out 
and dissociated in Hank’s balanced salt solution containing 0.25% Trypsin and 
2.21 mM ethylenediaminetetraacetic acid (EDTA) (Mediatech, Manassas, VA). 
Isolated cortical cells were plated into poly-D-lysine (Sigma-Aldrich, St. Louis, 
MO) treated tissue culture flasks.  The mixed glial cultures for the preparation of 
microglia were maintained in high glucose Dulbecco’s Modified Eagle Media 
(DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% horse serum, 2.5% 
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fetal bovine serum, and an antibiotic/antimycotic cocktail containing 100 I.U. 
penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B.   The mixed 
glial cultures were incubated for 8-10 days at 37 o C.  Microglia were then 
dislodged by vigorous shaking, plated, and used for experiments the following 
day.  
 
Membrane Ruffling and Quantification   
Microglia plated on poly-D-lysine treated glass coverslips were serum 
starved for four hours in DMEM then stimulated for 5 or 10 minutes with ATP 
(Sigma-Aldrich, St. Louis, MO) or 10 min with MCP-1 (Peprotech Inc., Norwood, 
MA).  Compounds to be tested were incubated with the microglia in DMEM for 10 
minutes prior to chemoattractant exposure. In one series of experiments Ca2+-
free DMEM (Invitrogen) was used.  Cytoskeletal changes were visualized using 
phalloidin conjugated to AlexaFluor 488 (Invitrogen). 
Multiple photomicrographs (n ≥ 4) of fields containing 1-8 cells were 
acquired for controls (DMEM) and each test group.  Morphology of the cells was 
evaluated by an investigator blind to the nature of the treatment and a score was 
given to each cell using the following criteria: “0” was given to cells which did not 
display any signs of membrane ruffling and had multiple apparent filopodia; “1” 
was given to cells which retained filopodia and lamellipodia, but  which also had 
regions on the cell membrane where ruffling was present; and “2” was given to 
cells which had withdrawn all their filopodia and displayed a fully ruffled 
phenotype.  The scores in each group were then summed and divided by the 
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number of cells assayed in that group to yield that group’s degree of membrane 
ruffling which was expressed in arbitrary units (A.U.).  Means for each group 
were compared and significant differences were determined via two-way ANOVA 
with post-hoc Bonferroni tests. 
 
Migration Assay  
Modified Boyden chambers were used as previously described (McCord et 
al. 2005). Briefly, 5x105 freshly isolated microglia were applied to the top portion 
of a Boyden chamber assembled with an 8 μm pore polycarbonate membrane.  
Media (DMEM) containing vehicle or chemoattractant (ATP or MCP-1) with or 
without compounds to be tested was added to the bottom of the chamber, and 
the cells incubated for four hours at 37oC.  The membranes were removed and 
microglia adhering to the top of the membrane were scraped off.  The membrane 
was oriented on a slide such that the cells that migrated to the bottom of the 
membrane were facing up. Vectashield Hardset mounting media (Vector Labs, 
Burlingame Ca) containing 4'-6-diamidino-2-phenylindole (DAPI) was applied to 
the membrane and a coverslip affixed to the slide.  DAPI positive cells were 
illuminated at 359 nm and visualized at 461 nm using a Zeiss Axioskop 2 
outfitted with a 20X objective.  A minimum of 5 random fields of cells were 
counted and averaged per membrane, and the results of at least three 
experiments were averaged. 
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ELISA assay   
Plates (96 well) were coated with 2 ng/ml capture antibody (tumor necrosis 
factor-α, MAB510 anti-rat antibody; interleukin-10, MAB519 anti-rat antibody; 
R&D Systems, Inc., Minneapolis, MN) overnight at 4oC. The plates were washed 
with Tris buffered saline (TBST) consisting of: 20 mM Tris pH 7.5, 150 mM NaCl, 
and 0.05% Tween 20. The plates were then blocked with 1% bovine serum 
albumin (BSA) in TBST for 1 hour.  A standard curve was prepared using 
recombinant protein standards. The standards as well as the unknowns were 
incubated for 1hr at room temperature and then washed with TBST. Biotinylated 
detection antibody (tumor necrosis factor-α, #BAF510 biotinylated anti-rat 
antibody; interleukin-10, #BAF519 biotinylated anti-rat IL10 antibody; R&D 
Systems, Inc., Minneapolis, MN) was added to each well at 100 ng/ml and 
incubated for 2 hrs at room temperature.  After incubation, the plates were 
washed three times with phosphate buffered saline (PBS) containing (in mM): 3.2 
Na2HPO4, 0.5 KH2PO4, 1.3 KCl, 135 NaCl (pH 7.4). Streptavidin conjugated to 
horseradish peroxidase (streptavidin-HRP) was added to each well followed by 
20 min incubation at room temperature. After washing, 100 μl of 3,3’,5,5’-
tetramethyl-benzidine (TMB) (Sigma-Aldrich, St. Louis, MO) was added and 
incubated for 5 minutes in the dark.  Finally, 50 μl of 1 M H2SO4 stop solution 
was added to each well and optical density was measured using a microplate 
reader set at 450 nm. 
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Griess reaction   
Supernatants from treated primary rat microglia cultures were collected, 
and clarified by centrifugation. Nitric oxide levels in the supernatant were 
determined using the Griess Reagent Kit (Invitrogen) according to the 
manufacturer’s protocol. 
 
Calcium Imaging  
Intracellular calcium ([Ca2+]i) was measured using the ratiometric Ca2+ 
sensitive dye, fura-2 as previously described (Katnik et al. 2006).  Microglia, 
plated on coverslips, were incubated for 1 hour at 37oC in DMEM (Mediatech, 
Manassas, VA) containing 5 μM fura-2, acetoxymethylester (fura-2 AM; 
Invitrogen) and 0.1 % dimethyl sulfoxide (DMSO).  The coverslips were washed 
in physiological saline solution (PSS) consisting of (in mM): 140 NaCl, 5.4 KCl, 
1.3 CaCl2, 1.0 MgCl2, 20 glucose, and 25 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (pH adjusted to 7.4 with NaOH) prior to 
the experiments being carried out. A DG-4 high speed wavelength switcher 
(Sutter Instruments Co., Novato, CA) was used to apply excitation light of 
alternating wavelength (340/380nm). Fluorescent emission was captured using a 
Sensicam digital CCD camera (Cooke Corporation, Auburn Hills, MI) and 
recorded with Slidebook 3.0 software (Intelligent Imaging Innovations, Denver, 
CO). Changes in [Ca2+]i were calculated using the Slidebook 3 software. 
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DAF Imaging  
Nitric oxide concentration was measured using the NO sensitive dye, 4-
amino-5-methylamino-2',7'-difluorofluorescein (DAF-FM).  Microglia plated on 
coverslips were incubated for 1 hour at 37oC in DMEM (Mediatech) containing 
5μM DAF-FM (Invitrogen) and 0.1 % DMSO.  The coverslips were washed in 
PSS prior to NO measurements.  DAF-FM loaded cells were illuminated at 488 
nm and visualized at 510 nm, using the same instrumentation described for 
calcium imaging experiments.  Background fluorescence was determined by 
measuring fluorescent intensities in areas between cells and was subtracted from 
the raw intensity values. Fluorescent intensity was expressed as arbitrary units. 
 
Data Analysis   
Analysis of measured intracellular [Ca2+] responses was conducted using 
Clampfit 9 (Molecular Devices, Union City, CA).  Statistical analysis was 
conducted using SigmaPlot 9 and SigmaStat 3 software (Systat Software, Inc., 
San Jose, CA).  Two-way ANOVA procedures with appropriate post-hoc tests 
were used to analyze data from the calcium imaging and migration experiments, 
while a three-way ANOVA procedure with post-hoc Tukey’s test was used to 
analyze data from the NO imaging experiments.   
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Reagents   
The sigma ligands DTG and metaphit were obtained from Tocris 
Bioscience (Ellisville, MO).  The microglial activator MCP-1 was purchased from 
Peprotech Inc., (Norwood, MA), ATP and LPS from Sigma-Aldrich (St. Louis, 
MO), thapsigargin from Alomone Labs (Jerusalem, Israel), and ionomycin from 
Calbiochem (San Diego, CA).  All other reagents were purchased from Sigma-
Aldrich and were of analytical grade or higher. 
 
Results 
 
Sigma receptor activation suppresses changes in microglia morphology in 
response to chemoattractant stimulation.   
ATP released from degenerating neurons activate microglia during brain 
injury (Davalos et al. 2005).  ATP binds purinergic receptors on microglia and 
causes microglia to change shape and migrate to the site of injury (Honda et al. 
2001).  To study these phenomena, microglia were treated with ATP and labeled 
using phalloidin, which binds to the actin cytoskeleton. Unstimulated microglia 
exhibited discrete, actin rich filopodia (Figure 1A and 1D). Upon stimulation with 
ATP (100 µM), for either 5 min (Figure 1B) or 10 min (Figure 1E) microglia 
retracted their filopodia and aggregated actin along the leading edge of the cell 
membrane in a manner consistent with membrane ruffling.  Administration of the 
sigma receptor agonist DTG (100 µM) 10 min prior to and during ATP exposure 
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decreased the aggregation of actin in the leading edge and promoted the 
retention of filopodia (Figure 1C and 1F).  DTG treatment alone resulted in cells 
which were morphologically indistinguishable from control (data not shown).  
Since ATP-induced retraction of filopodia is an extracellular Ca2+-independent 
process, experiments were also carried out in nominal extracellular Ca2+.  In the 
absence of extracellular Ca2+, microglia exhibited normal morphology, and 
filopodia were readily observed (Figure 1G).  Upon application of ATP (5 min), 
filopodia were retracted and membrane ruffling occurred (Figure 1H), and this 
membrane ruffling was still inhibited by the addition of DTG (Figure 1I). 
58 
 
 
Figure 1.  Sigma receptor activation suppresses changes in microglia 
morphology in response to chemoattractant stimulation.  
Photomicrographs of primary rat microglia cultures exposed to vehicle (0.1% 
DMSO in DMEM) (A, D, G), 100 μM ATP for 5 min (B, H) and 10 min (E), or 100 
μM ATP for 5 min (C, I) and 10 min (F) in the presence of 100 μM DTG.  
Microglia in A-F were treated in normal DMEM, whereas microglia in G-I were 
treated in Ca2+-free DMEM.  All insets represent magnified image (2.7x). Scale 
bar = 2 μm. 
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Sigma receptor activation significantly decreases membrane ruffling 
induced by ATP. 
The changes in membrane structure were quantified to determine if 
activation of sigma receptors altered the morphological response to ATP.  ATP 
treatment significantly increased the degree of membrane ruffling relative to the 
DMEM control (Figure 2).  Furthermore, while in the control group no cells were 
found to show complete membrane ruffling (n = 63), 62% of cells in the ATP 
treatment group showed this phenotype (n = 53).  DTG treatment alone had no 
effect on membrane morphology, with 11 of the 12 cells examined showing no 
evidence of membrane ruffling.  However DTG pretreatment reduced the 
response to ATP, as evident by the significant reduction in the degree of 
membrane ruffling induced by the purine (Figure 2).  The percentage of cells 
which exhibited membrane ruffling decreased to 11% when DTG was co-applied 
(n = 44). 
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Figure 2.  Sigma receptor activation significantly decreases membrane 
ruffling in microglia stimulated with ATP. 
Degree of membrane ruffling assessed as described in the methods section.  
Microglia were preincubated with vehicle, or DTG (100 μM DTG) for 5 minutes 
then stimulated with DMEM or ATP (100 μM).  Bars represent means ± SEM.  
Asterisks indicate significant differences between DMEM and ATP within Control 
(no DTG, p < 0.001) and DTG groups (p < 0.001). Pound symbol indicates 
significant difference between Control and DTG within the ATP group (p < 0.001). 
Significance was determined via two-way ANOVA with post-hoc Tukey’s Test. 
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The microglial migratory response to chemoattractant application is 
suppressed by sigma receptor activation.  
A modified Boyden chamber was used to measure the chemotaxis of 
freshly isolated microglia in response to ATP, with and without DTG present.  
ATP (100 µM) promoted a ten-fold increase in the number of microglia that 
migrated across the membrane relative to control (Figure 3A). This increase in 
migration was statistically significant (p < 0.001) and similar to that previously 
reported (Honda et al. 2001).   DTG (300 μM) alone had no effect on microglial 
migration (p = 0.47), but co-application of DTG with ATP significantly (p < 0.0001, 
n = 3) depressed the ATP-evoked migration of microglia (Figure 3A) by 72.68 ± 
3.55% relative to control (ATP and no DTG).  In the presence of DTG, ATP failed 
to evoke a statistically significant increase in migration above that observed when 
DMEM was applied (p = 0.076).   
The chemokine MCP-1, which binds the CCR2 receptor (Ogilvie et al. 
2004), was also tested to determine whether sigma receptor mediated inhibition 
of migration was limited to the effects elicited by purinergic receptors. Application 
of MCP-1 (10 nM) caused a five-fold increase in the number of microglia that 
migrated through the membrane compared to control (Figure 3B). This increase 
in migration was less than that observed with ATP, but consistent with the 3- to 
4-fold increase in macrophage and microglial migration reported for this 
concentration of MCP-1 (Dzenko et al. 2001; Peterson et al. 1997).  Co-treatment 
with 300µM DTG significantly depressed MCP-1-induced microglial migration 
relative to the control group (p < 0.001, n=4).  Furthermore, there was no 
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statistical significance between MCP-1 and DMEM-induced migration in the 
presence of DTG (p = 0.56, Figure 3B).  
Figure 3.  The microglial migratory response to chemoattractant application 
is suppressed by sigma receptor activation. 
Microglial migration was assayed using a Boyden chamber fitted with a 
polycarbonate membrane containing 8μm pores.  Microglia (500,000 cells) were 
placed in the upper chamber and control media, 100 μM ATP (A) or 10 nM MCP-
1 (B) were added in the absence and presence of 300 μM DTG to the bottom 
chamber.  Microglia were allowed to migrate for 4 hrs at 37 °C, then stained with 
DAPI and counted. Asterisks indicate a significant difference between ATP (A; p 
< 0.001, n = 6) and MCP-1 (B; p < 0.01, n = 4) from DMEM within the Control 
group (no DTG). Pound symbols indicate significant difference between Control 
and DTG within the ATP (A; p < 0.001) and MCP-1 (B; p < 0. 01) groups, 
respectively. In both cases significance was determined by two-way ANOVA 
followed by post-hoc Bonferroni tests.  
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The microglial inflammatory response is suppressed by sigma receptor 
activation.  
To ascertain whether sigma receptors modulated the pro-inflammatory 
response of microglia, cytokine, and NO production evoked by LPS were 
examined after pretreatment with DTG. LPS activates microglia and causes 
robust increases in cytokine production (Hoffmann et al. 2003).  Microglial 
cultures were preincubated with varying concentrations of DTG (50-1000μM) for 
30 minutes and the cells were then activated with LPS (1μg/ml). TNFα and IL10 
levels in the supernatant were measured using ELISA and NO levels were 
quantified with the Greiss reaction. DTG suppressed both cytokine and NO 
production in a concentration dependent manner (Figure 4). Fits of the data 
determined IC50 values of 338.9, 109.6, and 166.0µM for DTG inhibition of TNFα, 
IL10, and NO release, respectively (n = 4 for all groups tested).   
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Figure 4.  The microglial inflammatory response is suppressed by sigma 
receptor activation. 
Primary microglial cultures were incubated with LPS (1 μg/ml) for 24 hrs and in 
Levels in the supernatant of TNFα and IL10 were measured by ELISA, while NO 
was measured by the Greiss reaction.  Data points represent mean ± SEM for 
TNFα, IL10, and NO levels as a function of DTG concentration (n=4 for all 
groups). Lines indicate best fits to the data using a Langmuir-Hill equation and 
yielded IC50 values of 338.9, 109.6, and 166.0µM with Hill coefficients of 1.90, 
1.94, and 1.4 for TNFα, IL10, and NO release, respectively.  
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Transient intracellular calcium signaling is suppressed by sigma receptor 
activation. 
Changes in intracellular calcium are a critical component of the signaling 
cascade triggering the immune response of microglia. Given that sigma receptors 
regulate intracellular calcium concentrations ([Ca2+]i) in neurons (Katnik et al. 
2006), it seemed prudent to examine the effects of sigma receptor activation on 
changes in [Ca2+]i following microglia stimulation.  Focal application of 300 µM 
ATP (10 sec) onto microglia produced intracellular calcium increases of 140.4 ± 
16.2 nM in ~90% of cells tested (Figure 5A).  Following pretreatment (10 min) 
with 100 µM DTG, the ATP-elicited increases in [Ca2+]i were reduced by 82 ± 
16.4% (n=39), which was statistically significant (p < 0.001, Figure 5C). To 
confirm that DTG was acting via sigma receptors, cells were preincubated with 
the irreversible sigma receptor antagonist metaphit.  Pretreatment with metaphit 
(50 μM, 1 hr, room temperature) abolished the inhibitory effects of DTG on ATP-
induced [Ca2+]i increases (Figure 5B), such that no statistically significant 
difference (p = 0.52) existed between the ATP-induced [Ca2+]i responses 
observed in the absence (ATP + Met) and presence of DTG (ATP + DTG + Met) 
(Figure 5C).  
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Figure 5.  Transient intracellular calcium signaling evoked by ATP was 
suppressed by sigma receptor activation.  
Representative traces of [Ca2+]i as a function of time recorded during ATP (300 
µM) stimulation in the absence (Control) and presence of DTG (100 μM), without 
(A) or with (B) Metaphit (50 μM, 1 hr, room temperature).  C, Mean change in 
peak [Ca2+]i (± SEM) measured in the above treatment groups. Asterisk denotes 
significant difference (p < 0.05, n = 25), as measured by one-way ANOVA with 
post-hoc Dunn’s test using ATP as control.  
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Basal intracellular calcium increases are suppressed by sigma receptor 
activation.  
To determine whether DTG could inhibit the sustained increase in [Ca2+]i 
associated with the LPS-induced inflammatory response (Boddeke et al. 1999; 
Hoffmann et al. 2003), microglia were treated with LPS for 24 hours and then the 
basal intracellular calcium was measured. Treatment with LPS evoked a 46.1 ± 
11.0% increase in [Ca2+]i relative to control cells and this increase was 
statistically significant (p < 0.05, n = 31 Figure 6).  In contrast, in cells pretreated 
with 300 µM DTG, LPS failed to evoke increases in [Ca2+]i (Figure 6).  This 
inhibition of basal [Ca2+]i by DTG was statistically different from LPS treatment 
alone (p < 0.05, n = 31).  These results are consistent with the hypothesis that 
sigma receptors inhibit the inflammatory response elicited by LPS via the 
inhibition of LPS-induced increases in intracellular calcium. 
68 
Figure 6.  Basal intracellular calcium increases are suppressed by sigma 
receptor activation.  
Microglia, plated on poly-D-lysine coverslips, were stimulated for 24 hours with 
LPS (1μg/ml) in the absence (Vehicle) and presence of 300 μM DTG.  Mean 
basal calcium levels (± SEM) were measured using fura-2 calcium imaging.  
Values represent measurements from three pooled experiments each having a 
minimum of 30 cells per group.  Asterisks denote statistical difference (p < 0.05, 
n = 31) between Media and LPS treatment groups within the Vehicle group, and 
pound symbols denote significant difference between Vehicle and DTG within the 
LPS treatment group (p < 0.05, n=31).  Statistical difference was determined 
using a two-way ANOVA with post-hoc Bonferroni test. 
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Increases in intracellular calcium are sufficient to induce membrane 
ruffling in microglia. 
The calcium ionophore ionomycin was used to increase intracellular 
calcium in microglia via a pathway distinct from the sigma receptor-sensitive 
influx pathways activated in response to ATP, MCP-1 and LPS. Ionomycin 
treatment alone altered the morphology of microglia by promoting retraction of 
filopodia and inducing membrane ruffling when compared to control (Figure 7A 
and 7B). Unlike the results obtained when ATP was used to stimulate actin 
rearrangement, DTG was unable to inhibit ionomycin-induced membrane ruffling 
(Figure 7C).  Quantification of the results obtained with ionomycin and DTG 
treatment is summarized in Figure 7D.  Ionomycin evoked a statistically 
significant increase in the degree of membrane ruffling both in the absence and 
presence of DTG preincubation, and no significant interaction was noted 
between sigma receptor stimulation and the response to the ionophore.  These 
data show that increasing [Ca2+]i is sufficient to promote such changes in 
microglial morphology.  Moreover, the inability of DTG to decrease these 
ionomycin-evoked changes to the membrane suggest that sigma receptors are 
acting at the level of [Ca2+]i and not at downstream targets of this molecule. 
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Figure 7.  Increases in intracellular calcium induce membrane ruffling in 
microglia. 
Micrographs of phalloidin stained microglia treated with vehicle (DMSO, A), 1μM 
ionomycin for 5 minutes (B), and 1μM ionomycin + 100μM DTG.  D, Bar graph of 
degree of membrane ruffling determined for the indicated conditions.  Bars 
represent means ± SEM.  Asterisks indicate a significant difference between 
DMEM and Ionomycin treatment groups (p < 0.001). Significance was 
determined via two-way ANOVA with post-hoc Tukey Test. All insets represent 
magnified image (2.7x). Scale bar = 2 μm. 
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Microglial migration is a calcium dependent process which is not restored 
by ionomycin treatment. 
We next investigated whether ionomycin could overcome the blockade of 
microglial chemotaxis observed following sigma receptor activation. The 
membrane ruffling evoked by ionomycin was not associated with an increase in 
chemotaxis, and the number of migrating cells observed in response to 
ionomycin treatment was similar to that observed with vehicle alone (Figure 8A).  
Chemotaxis was observed as before in response to ATP, and it was significantly 
inhibited by co-administration of DTG.  However, microglial migration in response 
to ATP was disrupted by ionomycin treatment alone (Figure 8A).  In contrast to 
the observed effects on the microglial morphological response, the addition of 
ionomycin failed to promote microglial chemotaxis in the presence of ATP and 
DTG, instead significantly further decreasing migration relative to that observed 
in the ATP+DTG group.  
 
Microglial migration is independent of calcium release from internal stores 
but requires calcium influx. 
To determine the source of increased [Ca2+]i necessary for microglial 
migration, calcium release from intracellular stores and influx from the 
extracellular media were selectively blocked prior to ATP-stimulation.  The 
sarcoplasmic-endoplasmic calcium ATPase inhibitor thapsigargin was used to 
deplete calcium from the ER by blocking reuptake. Pretreatment with 10 μM 
thapsigargin alone, failed to suppress the migratory response to ATP (Figure 8B). 
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In thapsigargin treated samples, 100 μM ATP stimulated cell migration averaged 
747.0 ± 190 cells per field compared to 683 ± 187 cells per field in control 
samples (p = 0.67, n = 4) . The pan-selective calcium channel blocker La3+ was 
employed to block calcium channel mediated influx through the plasma 
membrane.  Lanthanum alone did not promote a significant change in migration 
when compared to control (p = 0.4897, n = 5). However, co-application of 50 μM 
La3+ with 100 μM ATP significantly suppressed microglial migration from 2069 ± 
121 cells per field (ATP alone) to 1636 ± 124 cells per field (ATP + La3+) (Figure 
8C, p = 0.022, n = 5).  Figure 8D summarizes these results, showing that under 
control conditions ATP induces a 320 ± 67 % increase in cell migration which is 
reduced to 183 ± 32% in the presence of 50 μM La3+.  Thus, inhibition of Ca2+ 
influx to the cell, such as that produced by sigma receptor activation, can prevent 
microglia chemotaxis. 
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Figure 8.  Microglial migration is independent of calcium release from 
internal stores but requires La3+-sensitive calcium influx. 
A, Microglial chemotaxis in response to ATP (100μM) in the absence and 
presence of DTG (300μM) and DTG with ionomycin ( μM). Data were analyzed 
via two-way ANOVA with post-hoc Tukey test. Asterisk indicates a statistical 
difference from respective controls (p <0.001 for all), pound symbol indicates a 
statistical difference from ATP alone (p <0.001 for all), and dagger indicates 
statistical significance from ATP+DTG (p <0.05 for all). B, Microglia migration 
induced by 300μM ATP without and with pretreatment of the cells with 10μM 
thapsigargin for 30 min (37°C) (Thapsigargin). Asterisk indicates a statistical 
difference from control (p <0.05). Bar represent means ± SEM, n = 3. C, 
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Microglia migration evoked by 300μM ATP in the absence (Control) and 
presence of 50μM La3+. Asterisk indicates a statistical difference from Control (p 
< 0.001), pound symbol indicates a statistical difference from ATP alone (p < 
0.01). Bar represent means ± SEM, n = 3. Statistical significance was determined 
by two-way ANOVA followed by post-hoc Bonferroni multiple comparison tests. 
D, Relative ATP induced migration in the absence (Control) and presence of 
50μM La3+. Asterisk denotes statistical difference (p < 0.05 by student’s T test). 
 
 
Calcium influx restores nitric oxide production following sigma receptor 
activation in LPS stimulated microglia cells. 
Increases in basal [Ca2+]i are integral to NO production in mouse microglia 
(Hoffmann et al. 2003). Experiments were conducted to determine if ionomycin 
facilitated Ca2+ influx would overcome the inhibitory effects of DTG on LPS-
induced NO production. Primary microglia were preincubated (30 min) with 
vehicle (0.1% DMSO in DMEM), DTG (300 µM), ionomycin (1 µM), or ionomycin 
+ DTG in the presence and absence of LPS (1 µg/ml) for 24 hours. Nitric oxide 
levels were measured using the intracellular NO indicator DAF-FM (Figure 9). 
LPS stimulation alone increased NO levels 138.7 ± 10.87% compared to vehicle 
(p < 0.001, n = 455).  Co-application of DTG with LPS resulted in a statistically 
significant suppression of NO levels (p < 0.001, n = 461), which were 22.2 ± 
6.36% higher than that of the DTG control group.  Application of LPS in the 
presence of ionomycin produced an increase in NO similar to that observed 
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when LPS was administered alone, such that NO levels were 129.9  ± 10.36% 
greater than that of the ionomycin control group (p < 0.001, n = 446). In contrast 
to the results observed for ATP-induced migration, addition of ionomycin to the 
LPS + DTG group was able to overcome the inhibitory effects of sigma receptor 
activation.  When ionomycin was co-applied with LPS and DTG 
(LPS+DTG+Iono) intracellular NO levels were increased by 86.1 ± 8.43% from 
DTG+Iono control (p < 0.001, n = 418).  These values were significantly greater 
than those observed for the LPS + DTG group (p < 0.001, n = 418), and similar to 
those elicited by the LPS + Iono group (p = 0.562, n = 446).  
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Figure 9.  Calcium influx restores nitric oxide production following sigma 
receptor activation in LPS stimulated microglia.  
Relative levels of NO produced by microglia under control condition (DMEM), in 
the presence of 300µM DTG (DTG), and following application of 1μM ionomycin 
alone (Iono) and with 300µM DTG (Iono + DTG). Microglia were also treated for 
24 hrs with LPS (1μg/ml) alone (LPS), LPS and 300μM DTG (LPS+DTG), LPS 
and 1μM ionomycin, and with a combination of the three compounds 
(LPS+DTG+IONO). Bars represent mean fluorescent intensities from DAF-FM 
loaded cells. Asterisk indicates statistical difference from DMEM treated cells, 
pound symbol denotes statistical significance from LPS treated cells, and dagger 
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indicates significance from LPS+DTG treated cells. In all cases p < 0.001, as 
determined by three-way ANOVA with post-hoc Tukey test (n ≥ 400 cells for all 
samples). 
 
 
Discussion 
The salient finding of this study is that sigma receptor activation can 
suppress multiple aspects of microglial activation, including the morphological, 
migratory and inflammatory responses to several known microglial activators. 
The results of this study provide insight into the role of sigma receptors in the 
regulation of immune system function.  Sigma receptor activation can inhibit 
membrane ruffling and migration of microglia, both of which are novel findings to 
the best of our knowledge.  As these processes are critical to the microglial 
response to injury, these findings reveals a novel aspect of the modulation of 
microglial activation by sigma receptors.  
Resting microglia exhibit a ramified morphology in vivo characterized by 
fine processes expressing chemosensitive receptors (Glenn et al. 1992).   
Studies using GFP-labeled microglia in vivo demonstrated that these processes 
are highly motile and quickly move towards ATP released by injured neurons 
(Davalos et al. 2005). Upon further activation in vivo, these processes are 
withdrawn and the microglia take on an amoeboid phenotype which is associated 
with an inflammatory state (Kreutzberg 1996; Lyons et al. 2000).  In vitro, 
membrane ruffling decribes the cytoskeletal re-arrangements critical for the 
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movements of microglial filopodia.  Our results demonstrate that sigma receptor 
activation blocks the formation of membrane ruffles in response to ATP 
application.  Metabotropic P2Y12 receptors, which evoke increases in [Ca2+]i in 
microglia (Ohsawa et al. 2007), are critical to the induction of membrane ruffling 
by ATP exposure (Honda et al. 2001).  ATP also elicits a transient increase in 
intracellular calcium via the activation of ionotropic P2X4 receptors expressed in 
microglia.  Intracellular calcium is an important co-factor in the process of 
membrane ruffling, since either depression of intracellular Ca2+ with BAPTA or 
deletion of the Ca2+-binding domain of Iba1, which is involved in ATP-induced 
membrane ruffling in microglia (Kanazawa et al. 2002; Ohsawa et al. 2000), 
inhibits agonist-elicited actin rearrangement in these cells (Ohsawa et al., 2000).  
Elevations in intracellular calcium have also been implicated in macrophage-
colony stimulating factor (M-CSF)-evoked membrane ruffling in microglia 
(Ohsawa et al., 2000).  Our studies show that increasing [Ca2+]i in microglia with 
ionomycin treatment is sufficient to trigger membrane ruffling. Similarly, in rat 
microglia/astrocyte co-cultures, the calcium ionophore calcimycine/A23187 
evoked a loss of ramifications in microglia (Kalla et al. 2003).  Sigma receptor 
activation suppressed both the ATP mediated calcium transient and membrane 
ruffling which suggests that the calcium increase is linked to membrane ruffling.  
Sigma receptor activation was unable to inhibit the ionomycin-induced membrane 
ruffling, indicating that sigma receptors are acting upstream of the calcium 
elevation in this pathway. 
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A second pathway which is [Ca2+]i-independent is able to induce 
membrane ruffling in microglia.  Previous studies have shown that purinergic 
receptor mediated increases in intracellular calcium are necessary for migration 
but not membrane ruffling in these cells (Honda et al. 2001; Ohsawa et al. 2007).  
Sigma receptor activation depressed membrane ruffling in the absence of 
extracellular Ca2+ and in conditions under which the Ca2+-independent 
membrane ruffling induced by ATP is observed (Honda et al. 2001).  Thus, sigma 
receptor activation is able to disrupt membrane ruffling both by preventing [Ca2+]i 
increases which may stimulate membrane ruffling and by blocking the Ca2+-
independent pathway.   
While both membrane ruffling and migration in response to ATP are 
dependent on P2Y12 receptor activation and intracellular calcium signaling, 
migration must also incorporate chemoattractant sensing and directionality.  In 
our migration studies we saw robust migration in response to ATP and MCP-1, 
both of which induce migration through a pertussis toxin sensitive Gi/o-protein 
(Dzenko et al. 2001; Honda et al. 2001; Sozzani et al. 1994).  Migration induced 
by both chemoattractants was inhibited by sigma receptor activation, suggesting 
that sigma receptors inhibit migration either by direct interaction with the Gi/o-
protein or by interfering with downstream calcium signaling.  Interestingly, unlike 
membrane ruffling, increasing intracellular calcium levels with ionomycin failed to 
restore microglial migration in the presence of sigma receptors.  In fact, inclusion 
of ionomycin effectively suppressed ATP induced migration.  This effect may be 
due to ionomycin-induced decreases in purinergic receptor signaling, which has 
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been reported (Hoffmann et al. 2003).  Alternatively, the homogeneous 
elevations in [Ca2+]i produced by ionomycin treatment may saturate and disrupt 
any directional effects produced by the purinergic signaling.  Similarly, the Ca2+ 
ionophore, A23187, disrupts microglial migration in response to complement 5a 
(Nolte et al. 1996).  In contrast, depletion of intracellular calcium stores with 
thapsigargin had no effect on migration, whereas the calcium channel inhibitor 
lanthanum partially suppressed microglial migration in response to ATP.  This 
latter finding is consistent with ionotropic P2X4 receptor signaling being essential 
to ATP induced microglial activation, which has been reported (Ohsawa et al. 
2007).  Given that sigma receptor activation decreased the calcium signaling 
known to be essential for microglial migration, this is the likely mechanism by 
which sigma receptor activation suppresses movement of the cells.      
Another crucial component of microglial function is the induction of the 
inflammatory response.  Activation of sigma receptors in the peripheral immune 
system potently suppresses the inflammatory response to a variety of stimuli 
(Bourrie et al. 2002).  It was proposed that these anti-inflammatory effects were 
mediated by sigma receptor-induced interleukin-10 (IL10) production (Zhu et al. 
2003).  However, studies on sigma receptor-mediated immunosuppression in 
RAW 264.7 macrophages suggested that IL10 is not always involved in these 
responses (Gannon et al. 2001).  This latter observation is consistent with our 
finding that IL10 production in response to LPS treatment was decreased with 
similar kinetics to reductions of TNF-α and NO production.  This observation 
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implies that sigma receptor activation affects signaling upstream of protein 
synthesis-dependent processes in the inflammatory response.    
Sustained increases in basal intracellular calcium levels are integral to the 
induction of the inflammatory response (Hoffmann et al. 2003).  Sigma receptor 
activation reduces the capacity of microglia to generate this sustained increase in 
calcium in response to LPS.  This is associated with a decreased release of 
cytokines and NO.  Reintroduction of calcium with ionomycin overcame the 
sigma receptor activation induced blockade of NO production. 
Our results showing that activation of sigma receptors suppresses ATP-
induced [Ca2+]i in microglia suggest that sigma receptors are inhibiting P2X 
receptors in these cells, since these channels account for most of the increase in 
[Ca2+]i observed in our experiments (data not shown).  Previous studies, 
including works from our laboratory, have shown that sigma receptors couple to 
both voltage-gated and ligand-gated ion channels (Aydar et al. 2002; Herrera 
2007; Zhang and Cuevas 2002; Zhang and Cuevas 2005).  Thus, this 
observation is consistent with the hypothesis that sigma receptors couple to a 
diverse group of ion channels.  While the regulation of these plasma membrane 
ion channels will affect [Ca2+]i, sigma receptors also affect other proteins which 
influence [Ca2+]i, including the IP3 receptor of the endoplasmic reticulum and the 
BiP chaperone found in the mitochondrion-associated ER membrane (Hayashi 
and Su 2001; Hayashi and Su 2007). However, the fact that sigma receptors 
affect membrane ruffling in the absence of Ca2+ signaling indicates that the 
influence of sigma receptors on microglial function is not limited to the regulation 
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of Ca2+ signaling alone.  Thus, the mechanisms by which sigma receptors 
regulate the activity of microglia remain to be fully elucidated.   
Activated microglia are associated with neurodegenerative disease 
progression (Streit et al. 2004), and the presence of  activated microglia is linked 
to increased neuronal damage.  In contrast, ablation of microglia is also 
associated with increased damage (Lalancette-Hebert et al. 2007), which shows 
that microglia play a complex part in the etiology of neurodegenerative disease.  
Our findings support and expand upon the theory that sigma receptors have 
potent immunoregulatory properties (Bourrie et al. 1995; Bourrie et al. 2002).  
Prior to our work, the relationship between sigma receptors and microglia had 
only been studied in an in vitro HIV-1 infection model (Gekker et al. 2006).  Our 
studies shed light on the mechanism by which sigma receptors modulate the 
function of microglia in response to brain injury.   
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Abstract 
Stroke induced brain injury is the third leading cause of death and disability in the 
United States. A major limitation of current stroke therapies is the need to treat 
candidate patients within three hours of stroke onset.  Human umbilical cord 
blood cell (HUCBC) and the sigma receptor agonist 1,3, di-o-tolylguanidine 
(DTG) administration both caused significant reductions in brain damage in the 
rat middle cerebral artery occlusion model of stroke when administered at 
delayed timepoints.  In vivo, these treatments suppress the infiltration of 
peripheral lymphocytes into the brain in addition to decreasing 
neurodegeneration.  It appears that neuroprotection afforded by both treatments 
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is a product of their actions on the peripheral immune system as well as a direct 
effect on the ischemic brain tissue.  An ex vivo organotypic slice culture (OTC) 
model to was utilized to characterize the efficacy of these treatments in mitigating 
neurodegeneration in ischemic brain tissue in the absence of the peripheral 
immune system. Slice cultures subjected to oxygen glucose deprivation (OGD) 
had significantly elevated levels of degenerating neurons and microglial nitric 
oxide production when compared to their normoxia counterparts.  HUCBC but 
not DTG treatment reduced the number of degenerating neurons and the 
production of microglia derived nitric oxide in slice cultures subjected to OGD 
back to levels seen in the normoxia controls.  These data show that HUCBC 
treatment can mediate direct neuroprotection and suppress innate inflammation 
in ischemic brain tissue in the absence of the peripheral immune system, 
whereas DTG requires peripheral effects to mediate neuroprotection.  These 
experiments yield insight into the mechanisms by which neuroprotective 
treatments function at delayed timepoints following stroke. 
 
Introduction 
Currently the only FDA approved treatment for ischemic stroke is 
recombinant tissue plasminogen activator (Alteplase) (Marler and Goldstein 
2003).  This treatment works by dissolving the blood clot occluding the offending 
blood vessel.  Unfortunately its use is restricted to a short, 3-6 hour, time window.  
Beyond this time, apoptotic and inflammatory processes greatly diminish the 
therapeutic benefits of current treatments.  Furthermore this treatment increases 
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the risk for bleeding and only provides a modest (13%) benefit in mortality and 
morbidity to patients who are candidates for this treatment (Marler and Goldstein 
2003). 
 Attempts to develop therapies to increase neurosurvival have not been 
successful clinically thus far. The vast majority of trials to date have focused on 
reducing the buildup of intracellular calcium, neuronal firing, and free radicals.  
These therapies were developed in order to combat a phenomenon called 
excitotoxicity which is thought to damage neurons (Dirnagl et al. 1999).  
 Neuronal damage due to excitotoxicity is caused by the release of 
glutamate which causes overactivation of ionotropic AMPA and NMDA 
glutaminergic receptors on ischemic neurons.  The increased AMPA and NMDA 
receptor activation causes sodium and calcium to enter the cell where it can 
depolarize neurons and increase excitability and firing.  Under ischemic 
conditions this depolarization results in further metabolic demand and can drop 
ATP levels below those needed to maintain ionic homeostasis.  The resulting 
anoxic depolarization causes a further calcium influx which activates proapoptotic 
signaling cascades, causing free radical buildup, and neuronal death.  While 
these therapies have been successful in vitro, their efficacy in animal studies was 
restricted to early timepoints (<3 hrs).  Furthermore reducing excitability by 
blocking NMDA receptors or calcium channels was associated with intolerable 
side effects such as hallucinations and dizziness (NMDA) (Davis et al. 2000) and 
reductions in blood pressure (calcium channel blockers) (Horn et al. 2001). 
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Two experimental treatments which have shown a great deal of promise in 
experimental rat models of focal ischemia are human umbilical cord blood cells 
(HUCBC) (Vendrame et al. 2004) and 1,3-di-o-tolylguanidine (DTG) (Ajmo Jr et 
al. 2006).  The main advantage of these treatments over previous therapies lies 
in the fact that they can be given at clinically relevant timepoints (24 and 48 
hours post stroke for DTG and HUCBC respectively).  In the permanent middle 
cerebral artery occlusion (MCAO) model of stroke, injection of  HUCBC (106) 48 
hours (Newcomb et al. 2006) or administration of DTG (15mg/kg) 24 hours (Ajmo 
Jr et al. 2006) after stroke reduces infarct volume by up to 80% when compared 
to vehicle treated control.  Originally both treatments were thought to decrease 
infarct volumes by either reducing neuronal ion imbalances (DTG) (Katnik et al. 
2006) or replacing neurons (HUCBC).  Further studies have shown each of these 
treatments had profound effects on components of the immune system.   
HUCBC have been shown to migrate to injured brain and the spleen 
(Vendrame et al. 2004).   Subsequent studies showed that infiltration of the 
HUCBC into the brain was not required for neuroprotection (Borlongan et al. 
2004).  Sigma receptors are also found in the spleen at high densities and are 
expressed on lymphocytes and macrophages (Su 1991).  The spleen is 
important in ischemic pathology as splenectomy prior to stroke shows significant 
reductions in neurodegeneration (Ajmo et al. 2008).  T-lymphocytes in particular 
are known to be present in the spleen in large numbers and to contribute to 
stroke induced neurodegeneration (Offner et al. 2006; Yilmaz et al. 2006).  
Peripheral immune cells such as these migrate to the infarct and interact with 
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antigen presenting cells there to promote a proinflammatory immune response.  
One of the principal immune cell types present in the infarct and known to serve 
as antigen presenting cells is microglia (Morioka et al. 1993). 
Microglia, the innate immune cells of the brain, are normally kept in a 
quiescent ramified state (Streit 2002).  Upon stimulation by dying neurons, 
microglia become activated, assume an amoeboid phenotype, migrate to the site 
of injury, and release inflammatory mediators (Gibson et al. 2005).  Nitric oxide is 
a particular noxious mediator generated by inducible nitric oxide synthase which 
is upregulated in activated microglia which can interfere with neuronal respiration 
and induce apoptosis.  HUCBC and DTG have been shown to reduce microglial 
activation in vivo (Ajmo Jr et al. 2006; Newcomb et al. 2006).  DTG also 
suppresses microglial activation by blocking calcium signaling and reduces 
lipopolysaccharide (LPS) induced nitric oxide by this mechanism in vitro (Hall et 
al. 2008). 
The purpose of the present study was to determine whether the efficacy of 
HUCBC and DTG in vivo at delayed timepoints is solely due to the impact on the 
peripheral immune system or also involves direct effects on the ischemic brain 
tissue.  To study the effects of these therapies on ischemic tissue in the absence 
of the peripheral immune system; organotypic hippocampal slice cultures were 
subjected to oxygen glucose deprivation (OGD) in order to induce 
neurodegeneration.  Fluoro-Jade staining was used as a marker for degenerating 
neurons, while nitric oxide production was used to identify microglia which had 
differentiated into a neurodestructive phenotype.  
94 
Materials and Methods 
Animal Care 
All animal procedures were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals with a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Florida. 
Timed pregnant Sprague-Dawley dams were purchased from Harlan Labs 
(Indianapolis, IN), maintained on a 12 hr light/dark cycle (7 am – 7 pm) and given 
access to food and water ad libitum.  Neonatal rats birthed from time-pregnant 
dams were used for all experiments. 
Organotypic Slice Culture 
Organotypic slice cultures (OTC) were prepared using a method described 
(Stoppini et al. 1991), with slight adaptations. Postnatal day 8-10 rat pups were 
sacrificed by decapitation. Brains were removed and intact hippocampi were 
isolated in ice cold isotonic buffer (136.89 mM NaCl, 5.37 mM KCl, 169 nM 
Na2HPO4, 22.04 nM KH2PO4, 27.52 nM glucose, 59.01 mM sucrose). 400 µm 
hippocampal slices were prepared using a McIlwain Tissue Chopper (Mickle 
Laboratory Engineering Co. Ltd. Gomshall, Surrey, England). Only slices that 
appeared thin and translucent were selected for culture. Slices were then 
incubated for 90 min at 4˚C. Cultures were maintained on Millicell CM (Millipore 
Corp., Billerica, MA) inserts and placed in 6-well plates containing Neurobasal 
media supplemented with B27 and 5 mM L-glutamine. Slices were cultured for 14 
days in room air supplemented with 5%CO2 maintained at 37˚C, receiving partial 
media changes every 3-4 days prior to experimentation.  
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Oxygen Glucose Deprivation 
 Organotypic slices were subjected to 48 hrs of normoxia or oxygen 
glucose deprivation (OGD). Slices were assigned to 1 of 2 exposures (normoxia 
or OGD) and 1 of 2 treatments (media, or HUCBC). Immediately prior to 
exposure, inserts were transferred into new 6-well plates containing media, or 
106 HUCBC (Sigma Aldrich, St. Louis, MO). Media consisted of Dulbecco’s 
Modified Eagles Medium (DMEM; Mediatech, Herndon, VA) for normoxia or 
DMEM without glucose (Invitrogen, Carlsbad, CA) for OGD. HUCBC (AllCells) 
were thawed and resuspended in DMEM containing DNase (1ug/ml) to prevent 
aggregation.  HUCBC were washed twice and resuspended at a concentration of 
108 cells/ml.  HUCBC (106) were added to each well receiving treatment.  
Cultures were maintained in a standard tissue culture incubator during the 
normoxia exposure and a hypoxic chamber flushed with 1%O2, 5%CO2, and 
balanced N2 (CBS Scientific Co. Inc., Del Mar, CA) held at 37˚C during the OGD 
exposure.  
Fluoro-Jade Staining 
 Organotypic slice cultures were stained with Fluoro-Jade (Histochem, 
Jefferson, AR), which labels degenerating neurons.  This method was adapted 
from that originally developed (Schmued et al. 1997) and has been described by 
Duckworth et al. (2005).  Tissue was wet mounted and dried to glass slides.  
Slices were rehydrated by then exposure to absolute ethanol for 3 min followed 
by 70% ethanol and deionized water for 1 min each. Slices were oxidized using a 
0.06% KMnO4 solution for 15 min followed by three rinses of double distilled 
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water for 1 minute each.  Slices were stained in a 0.001% solution of Fluoro-Jade 
in 0.1% acetic acid for 30 min.  Slides were again rinsed, allowed to dry at 45oC 
for 20 min, cleared with xylene and cover slipped with DPX mounting medium 
(Electron Microscopy Sciences, Ft. Washington, PA).  
Nitric oxide imaging 
Nitric oxide levels were measured using the NO sensitive dye, 4-Amino-5-
methylamino-2',7'-difluorofluorescein (DAF-FM).  Organotypic slice cultures on 
Millicell inserts were incubated for 1 hour at 37oC in DMEM (Mediatech) 
containing 5μM DAF-FM (Invitrogen) and 0.1 % DMSO.  The slices were washed 
in PSS prior to NO measurements.  DAF-FM loaded slices were imaged using a 
DG-4 high speed wavelength switcher (Sutter Instruments Co., Novato, CA) 
which applied excitation light at 488 nm. Emitted fluorescence light was collected 
through the microscope objective (Zeiss; 2,5X Plan-Neofluar) and passed 
through an emission filter (510 nm) onto a Cooke SensiCam CCD camera 
(Cooke Corporation, Auburn Hills, MI).  Images were recorded with Slidebook 3.0 
software (Intelligent Imaging Innovations, Denver, CO). Nitric oxide levels were 
calculated using the Slidebook 3 software.  Fluorescent intensity was expressed 
as arbitrary units. 
Immunohistochemistry  
Slice cultures were fixed with 4% paraformaldehyde in phosphate buffered 
saline (PBS) at 4oC overnight.  Slice cultures were removed from the MilliCell 
inserts; wet mounted, and allowed to dry at 45oC for 1hr. The slides were rinsed 
with PBS (pH 7.2), and placed in permeabilization buffer containing 10% goat 
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serum, 3% 1M lysine, and 0.3% Triton X-100 in PBS for 1 hr at room 
temperature.  Next, sections were incubated overnight at 4°C in a PBS solution 
with 2% goat serum and 0.3% Triton X-100 and primary antibody in a humidified 
chamber, protected from light when necessary.  Slides were washed with PBS (3 
x 5 min) and incubated with a secondary antibody solution (PBS, 2% goat serum, 
0.3% Triton X-100) in a humidified chamber protected from light. The sections 
incubated with OX-42 mouse anti-rat (1:3,000, Serotec) were incubated with 
Alexa-Fluor® 594 goat anti-mouse secondary (1:300, Molecular Probes) After 
final washing the slides were cover slipped with Vectashield hard set mounting 
media with DAPI (Vector Laboratories, Burlingame, CA). 
 
 
Results 
Oxygen glucose deprivation significantly increases neurodegeneration and 
nitric oxide production in OTC. 
In order to characterize the response of the OTC to OGD, slices were 
subjected to varying OGD durations. The timepoints tested were 0, 12, 24, 36, 
and 48 hours following induction of OGD.  OTC were assessed for 
neurodegeneration and nitric oxide production by staining with Fluoro-Jade and 
DAF-FM, respectively.  OGD induced significant increases in Fluoro-Jade 
staining only in the 48 hour timepoint (p<0.05, n=4) as measured by one-way 
ANOVA with post-hoc Dunnett’s test using 0 hour as a control (Figure 1A).   
Significant increases in DAF-FM staining were seen in the 12, 24, and 48 hour 
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timepoints (p<0.01, n=6) (Figure 1B).   As the 48 hour timepoint had significant 
increases in Fluoro-Jade and DAF-FM staining it was used for the remainder of 
this study. 
 
Figure 1.  Oxygen glucose deprivation significantly increases 
neurodegeneration and nitric oxide production in OTC. 
Organotypic slice cultures were subjected to varying durations of oxygen glucose 
deprivation.  Neurodegeneration was assessed using Fluoro-Jade staining while 
nitric oxide production was determined with DAF-FM.  Graphs represent mean 
stained area values +\- SEM for Fluoro-Jade (A) and mean stained intensity 
values +\- SEM for DAF-FM staining (B).  Asterisk denotes significance (p<0.05) 
and (p<0.01) for (A) and (B) respectively as determined using one-way ANOVA 
with post-hoc Dunnet’s test using 0hr as control. Scale bars represent 500μm 
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HUCBC but not DTG significantly reduces Fluoro-Jade staining in OTC 
following OGD. 
Fluoro-Jade staining was used to identify neuronal damage in each of the 
treatment groups.  There was extensive Fluoro-Jade staining in all regions of the 
slice cultures in the OGD group (Figure 2D) when compared to the normoxia 
group (Figure 2A).  DTG treatment (100μM) prior to OGD induction (Figure 2E) 
failed to reduce Fluoro-Jade staining when compared to OGD alone (Figure 2D). 
Administration of 106 HUCBC prior to induction of OGD reduced Fluoro-Jade 
staining (Figure 2F).  Normoxic samples treated with HUCBC (Figure 2C) and 
DTG (Figure 2B) showed similar levels of Fluoro-Jade staining to the normoxic 
controls (Figure 2A). To determine whether treatments caused a significant 
decrease in neuronal death, levels of Fluoro-Jade staining were quantified.  
Mean levels of Fluoro-Jade staining were significantly increased (p=<0.001, n=9; 
Figure 2G) (p=<0.0009, n=10; Figure 2F) in the OGD treated sections when 
compared to normoxic controls. DTG treatment did not significantly decrease 
Fluoro-Jade staining when compared to OGD treatment alone (p=0.5119, n=9) 
(Figure 2G). HUCBC treatment in OGD groups decreased Fluoro-Jade staining 
significantly from the OGD control (p<0.05, n=6) (Figure 2G).  Statistical 
significance was determined by two-way ANOVA with post-hoc Bonferroni test. 
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Figure 2.  HUCBC but not DTG significantly reduces Fluoro-Jade staining in 
OTC following OGD. 
Photomicrographs depicting OTC under normoxic conditions treated with Vehicle 
(A), 100μM DTG (B), and 106 HUCBC (C) or OGD conditions treated with Vehicle 
(D), 100μM DTG (E), and 106 HUCBC (F).  (G) Mean Fluoro-Jade positive areas 
in DTG treated OTC showed no significant differences from vehicle controls in 
either normoxia or OGD conditions.  (F)  Mean Fluoro-Jade positive areas in 
HUCBC treated OTC showed significantly reductions in staining when compared 
to vehicle controls in OGD but not normoxic conditions. Asterisks denote 
significance (p<0.05) as determined by two-way ANOVA with post-hoc 
Bonferroni’s test. Scale bars represent 500μm 
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DTG treatment is ineffective in reducing Fluoro-Jade staining at multiple 
concentrations. 
 There is likely a discrepancy in the concentrations of DTG between the in 
vitro OTC and the in vivo MCAO models.  Therefore, a concentration response 
study was conducted to determine a concentration at which Fluoro-Jade staining 
would be reduced following OGD (Figure 3).  The concentrations of DTG used 
were 0, 30, 100, and 300μM.  This concentration range has been used to reduce 
neuronal death and microglial activation in vitro.  None of these concentrations 
reduced Fluoro-Jade staining following OGD.  The 300μM dose significantly 
increased Fluoro-Jade staining when compared to OGD alone (139.22+/-14.34%, 
p<0.001, n=6).  As only HUCBC showed efficacy in reducing Fluoro-Jade 
staining, only the effects of this treatment were explored with respect to NO 
production.  
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Figure 3.  DTG treatment is ineffective in reducing Fluoro-Jade staining at 
multiple concentrations. 
Relative levels of Fluoro-Jade stained area in slices incubated in 0, 30, 100, and 
300μM DTG prior to the induction of normoxia or OGD.  No concentrations tested 
decreased Fluoro-Jade staining; however, the 300μM DTG group subjected to 
OGD had significantly increased Fluoro-Jade stained area compared to OGD 
alone.  Asterisk denotes significance p<0.001 as determined using one-way 
ANOVA with post-hoc Dunnet’s test using 0μM DTG subjected to OGD as 
control. 
 
HUCBC treatment reduces DAF-FM staining in OTC following OGD. 
The intracellular dye DAF-FM was used to determine the extent of NO production 
in each of the treatment groups.  There was robust NO production in all regions 
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of the slice cultures in the OGD group (Figure 4C) when compared to the 
normoxia group (Figure 4A).  Administration of 106 HUCBC prior to induction of 
OGD reduced NO production (Figure 4D).  Normoxic samples treated with 
HUCBC (Figure 4B) showed similar levels of NO production staining to the 
normoxia controls.  To determine whether HUCBC treatment caused a significant 
decrease in NO production similar to that seen with the Fluoro-Jade staining, 
levels of DAF-FM staining were quantified (Figure 4E).  Mean levels of DAF-FM 
staining were increased 172.01+/-75.21% in the OGD treated sections when 
compared to normoxic controls.  This increase was significant (p<0.05, n=3). 
HUCBC treatment in OGD groups decreased DAF-FM staining 43.3+/-15.86%.  
This decrease was significant from the OGD control (p<0.05, n=3).  Significance 
was determined by two-way ANOVA with post-hoc Bonferroni’s test. 
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Figure 4.  HUCBC treatment reduces DAF-FM staining in OTC following 
OGD. 
Photomicrographs depicting OTC under normoxic conditions treated with vehicle 
(A), and 106 HUCBC (B) or OGD conditions treated with vehicle (C), and 106 
HUCBC (D).  (E)  Mean DAF-FM intensities in HUCBC treated OTC showed 
significantly reductions in staining when compared to vehicle controls in OGD but 
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not normoxic conditions. Asterisk denotes significance (p<0.05) as determined by 
two-way ANOVA with post-hoc Bonferroni’s test. Scale bars represent 500μm. 
 
HUCBC reduces the number of nitric oxide producing microglia in ischemic 
OTC. 
Microglia and neurons can produce NO in response to ischemia.  To determine 
whether the observed NO production was due to activated microglia, DAF-FM 
stained slices were also stained for the microglial marker CD11b.  In the 
normoxia slices NO production was observed in cells which did not exhibit 
CD11b immunoreactivity (Figure 5A).  In OGD treated slices NO production was 
much more prominent and overlapped with CD11b staining (Figure 5C).  HUCBC 
treatment in both normoxia (Figure 5B) and OGD treated (Figure 5D) slices led to 
similar patterns of staining which was indistinguishable from the normoxia 
controls.  Pearson’s correlation coefficient values from multiple images were 
pooled and averaged to determine whether the signal overlap between the 
CD11b and DAF-FM stains were significantly different between treatment groups 
(Figure 5E).  The Pearson’s correlation coefficient in the slices subjected to OGD 
was significantly increased 140.21+/-46.99% when compared to normoxic control 
(p<0.0012, n=6).  HUCBC treatment of OGD slices significantly reduced the 
Pearson’s correlation coefficient (p<0.01, n=7) such that it was not different from 
normoxia controls (0.3819, n=5).  Significance was determined by two-way 
ANOVA followed by Bonferroni post-hoc test. 
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Figure 5.  HUCBC reduces the number of nitric oxide producing microglia 
in ischemic OTC. 
Confocal micrographs depicting OTC double stained with DAF-FM (NO)(green) 
and CD11b (microglia)(red) under normoxic conditions treated with vehicle (A), 
and 106 HUCBC (B) or OGD conditions treated with vehicle (C), and 106 HUCBC 
(D).  (E)  Mean Pearson’s correlation coefficients demonstrated a significant 
increase in staining overlap between the DAF-FM in OTC subjected to OGD 
(p<0.0012).  HUCBC treatment significantly reduced this overlap (p<0.01).  
Asterisk denotes significance (p<0.05) as determined by two-way ANOVA with 
post-hoc Bonferroni’s test. Scale bars represent 50μm 
* 
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Discussion  
HUCBC and DTG have shown great promise in reducing ischemic 
neurodegeneration at delayed timepoints following MCAO.  The mechanisms by 
which these treatments are neuroprotective are unclear.  In vivo labeling studies 
have shown that both HUCBC and DTG bind to the brain and spleen (Su et al. 
1988; Vendrame et al. 2004).  The spleen is a lymphoid organ which contains 
peripheral lymphocytes which contribute detrimentally to the progression of 
ischemic injury (Ajmo et al. 2008).  There are both humoral and synaptic 
crosstalk between the brain and the spleen via the HPA axis and the splenic 
nerve, respectively (Elenkov et al. 2000).  To determine whether DTG and 
HUCBC have direct effects on the local microglial mediated inflammation and 
neurosurvival in brain tissue in the absence of peripheral immune cells; an 
organotypic hippocampal slice culture model of ischemia was utilized. 
Organotypic hippocampal slice culture is a superior model for the study of 
ischemic brain injury than dissociated neuronal or microglial cell cultures owing to 
the fact that functional connections between different cell types are maintained 
(Noraberg et al. 2005). In order to further characterize this model with respect to 
neurodegeneration, slice cultures were subjected to OGD at different timepoints 
and stained with Fluoro-Jade.  In this model system neurodegeneration 
increased in a time dependent manner following the induction of OGD with 
significant increases observed at the 48 hr timepoint.  
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The multiple inflammatory stimuli released by ischemic neurons in the 
slice cultures activate microglia by a mechanism which mimics the in vivo 
ischemic microenvironment more closely than traditional activators such as 
lipopolysaccharide.  Microglial activation is a hallmark of the neural response to 
injury (Streit et al. 2004).  Early stages of microglial activation, such as 
phagocytosis of cell debris (Streit et al. 2005) and the release of growth factors 
such as BDNF (Coull et al. 2005), can be neuroprotective.  Further activation of 
microglia can lead to the production of toxic pro-inflammatory cytokines (Dirnagl 
et al. 1999; Rothwell 1996) and reactive oxygen species including nitric oxide 
(Gibson et al. 2005).  Nitric oxide can exacerbate the effects of ischemia on 
neurons by competing for oxygen binding on cytochrome oxidase (Mander et al. 
2005).  Subsets of microglia, which produce high levels of nitric oxide, are likely 
neurotoxic and deleterious in the ischemic microenvironment.   
In this study the HUCBC treatment was neuroprotective but the DTG 
treatment was not.  This is intriguing as sigma receptor agonists reduce ischemia 
and acidosis induced death in dissociated neuronal cultures by reducing calcium 
influx into these neurons (Herrera et al. 2008; Katnik et al. 2006).  Furthermore 
sigma agonists suppress spreading depression and ionic imbalances in acute 
hippocampal slice preparations (Anderson and Andrew 2002; Anderson et al. 
2005).  As spreading depression and calcium dysregulation are central 
components of excitotoxic cell death, blocking these processes with DTG should 
have resulted in reduced Fluoro-Jade staining in slices subjected to OGD.   This 
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demonstrates that in this model, excitotoxic cell death and anoxic depolarization 
are not the primary mechanisms by which neurons die in this model. 
Sigma receptors also have potent anti-inflammatory properties which can 
reduce inflammation induced neuronal death.  In the organotypic slice culture 
microglia are the only immune cell type present.  Sigma receptors reduce 
microglial activation in vitro by suppressing intracellular calcium signaling (Hall et 
al. 2008).  By blocking intracellular calcium signals, many aspects of microglial 
activation such as membrane ruffling, migration, and cytokine production are 
impaired (Hall et al. 2008).  The 300μM DTG concentration, which completely 
suppressed microglial activation (Hall et al. 2008), resulted in the highest levels 
of Fluoro-Jade staining encountered, suggesting that some aspects of microglial 
activation are beneficial. This finding is in agreement with other studies which 
have showed that ablation of microglia is neurodestructive(Lalancette-Hebert et 
al. 2007). 
Sigma receptor activation also suppresses T-cell mediated immunity by 
upregulating production of the anti-inflammatory cytokine IL10 (Zhu et al. 2003).  
As microglia can interact with T-cells as antigen presenting cells (Morioka et al. 
1991), it is possible that modulation of this interaction by sigma receptor agonists 
such as DTG could result in the robust neuroprotection seen in vivo. The results 
shown here suggest that the neuroprotection mediated by DTG in vivo at delayed 
timepoints is mediated by effects on systems outside of the CNS such as the 
peripheral immune system.   
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While HUCBC treatment has been shown to reduce propridium iodide 
uptake in organotypic slice cultures, no studies have been performed to our 
knowledge which directly measure neuronal damage or the ensuing inflammatory 
response (Vendrame et al. 2005).  Here we show that HUCBC can reduce both 
neurodegeneration and microglial mediated inflammation.  HUCBC are 
composed of a mixture of cell types which are mainly leukocytes, with a small 
(<1%) fraction of stem cells which are also present (Pranke et al. 2001).  The 
mechanisms by which HUCBC directly promote protection are unclear, but may 
include the secretion of neurotrophic growth factors such as glial cell–derived 
neurotrophic factor (GDNF), epidermal growth factor (EGF), brain-derived 
neurotrophic factor (BDNF), and fibroblast growth factor (FGF) (Neuhoff et al. 
2007).  While cell to cell contact was prohibited by the membranes the slices 
were grown on, secreted factors such as these growth factors could decrease 
neurodegeneration.   
HUCBC significantly decreased the number of microglia which expressed 
NO.  This is in agreement with the finding that HUCBC therapy in vivo 
dramatically reduced the number of microglia present in the infarct (Newcomb et 
al. 2006).  Co-culture experiments in vitro demonstrate this effect is mediated by 
the production of pro-inflammatory cytokines by CD8+ T-cells, which induce 
microglial apoptosis following hypoxia (Jiang L 2006).   Similar experiments using 
a double transgenic PSAPP/Tg2576 mouse model of Alzheimer’s disease, 
demonstrated that HUCBC can decrease microglial activation by reducing 
CD40/CD40L interactions (Nikolic et al. 2008).  Microglial CD40 is an important 
111 
activation signal which is reduced by HUCBC treatment (Nikolic et al. 2008).  As 
HUCBC only decreased the incidence of NO producing microglia in the slice, 
decreasing microglial CD40 expression may be a mechanism by which HUCBC 
can cause this effect. 
HUCBC and DTG are both potent suppressors of ischemia induced 
neurodegeneration in vivo at delayed timepoints (Ajmo Jr et al. 2006; Vendrame 
et al. 2004).   Understanding the processes which these treatments modulate, 
should shed light on the mechanisms for halting the pathophysiological effects of 
ischemic injury.  These studies show that sigma receptor activation on ischemic 
brain tissue is not directly protective, suggesting that the target of this therapy is 
peripheral to the CNS.  A likely therapeutic target is the lymphocytes which 
infiltrate the infarct at delayed timepoints (Gee et al. 2007).  This interaction of 
peripheral immune cells and injured brain tissue could also mediate the 
protective effects of HUCBC seen in this study as they are composed primarily of 
lymphocytes and monocytes (Pranke et al. 2001), and that migration into the 
CNS is not required for this protection (Borlongan et al. 2004).  Further research 
into the effects of these treatments on the interaction between the CNS and the 
peripheral immune system should yield further insight into the mechanisms by 
which these two treatments reduce stroke induce brain injury. 
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The Spleen Contributes to Stroke Induced Neurodegeneration in an Indirect 
Manner 
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Abstract 
Stroke induced brain injury is the third leading cause of death and 
disability in the United States. Recent studies have shown that the spleen plays a 
major role in stroke pathology.  Following stroke, the spleen becomes reduced in 
size and cellular content.  Our lab has shown that removal of the spleen prior to 
MCAO reduces infarct volume by 80%.   This study sought to characterize the 
changes in spleen and brain over time following MCAO, and determine where 
splenocytes migrate to influence neurodegeneration.  To accomplish this, rats 
received intrasplenic injections of the dye CFSE five days prior to MCAO surgery, 
to label splenocytes.  Rats were sacrificed at varying timepoints following MCAO 
and brains and spleens were harvested for subsequent analysis.  The spleens of 
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animals were found to shrink by 24 hours post MCAO.  This effect was transient, 
with spleens regaining their size by 72 hours post MCAO.  Numerous labeled 
splenocytes were found in spleen, blood, and thymus.  Very few splenocytes 
were found in the brain and were restricted to blood vessels.  To determine 
whether the spleen influences the post stroke immune response by secreting 
cytokines, IL10 and IFNγ levels were studied in the brain and spleen.   IL10 
expression was found to significantly increase in the spleen and brain by 96 
hours post MCAO.  This increase in IL10 and IFNγ expression was blocked after 
treatments with HUCBC or DTG and likely reflects modulation of the immune 
response mediated by these treatments. 
 
 
 
 
 
Introduction 
Local inflammation has both beneficial and deleterious effects on ischemic 
lesions. When local inflammation activates the peripheral immune system, 
however, a much larger inflammatory response is elicited causing collateral 
destruction of the peri-infarct regions (Offner et al. 2006b).  The brain 
communicates with the immune system largely via direct innervation of lymphoid 
tissues and humoral control provided by the hypothalamic-pituitary-adrenal axis 
(HPA axis) (Chrousos 1995).   
 The thymus and the spleen become reduced in size (Offner et al. 2006b; 
Vendrame et al. 2006) upon induction of CNS ischemia.  Multiple groups have 
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associated this decrease in thymus and spleen size with profound leucopenia 
and an increased susceptibility to infection based on a lack of IFNγ producing T-
cells (Prass et al. 2003; Yilmaz et al. 2006).  This immunosuppression, while 
likely helpful at reducing permanent brain injury, can be reversed by 
administration of beta-adrenergic blockers such as propranolol (Meisel et al. 
2005; Prass et al. 2006).  The Offner group postulated that the decrease in 
spleen and thymus size was due to mass apoptotic cell death based on TUNEL 
immunoreactivity (Offner et al. 2006b).  Recent work in our lab has demonstrated 
that the spleen shrinkage is due, at least in part, to activation of alpha1 
adrenergic receptors located on the smooth muscle capsule by circulating 
catecholamines, and this shrinkage can be blocked by prophylactic 
administration of prazosin, an alpha1 receptor antagonist (Ajmo Jr. CT 2009).  
The induction of such profound immunosuppression indicates that the 
peripheral lymphoid organs can exacerbate ischemic injury.  The spleen in 
particular plays a critical role in the response to ischemic injury and its treatment 
at delayed timepoints.  Splenectomy two weeks prior to stroke effectively reduces 
infarct volume by 80% demonstrating a critical role for this organ in stroke 
pathology.  The importance of the spleen in stroke is also demonstrated by the 
finding that human umbilical cord blood cells (HUCBC) injected into rats receiving 
MCAO migrated primarily to the spleen and infarct (Vendrame et al. 2004).  
HUCBC therapy restores both spleen size and cellular content when compared 
to MCAO alone (Vendrame et al. 2005; Vendrame et al. 2006). 
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The spleen can modulate the peripheral immune system by secreting 
cytokines which can induce a pro-inflammatory (TH1) or anti-inflammatory (TH2) 
immune response.  Two important cytokines in this process are IFNγ and IL10.  
IFNγ and IL10 induce TH1 and TH2 responses, respectively, and can serve as 
surrogate markers for the inflammatory state following ischemia. 
Experiments performed here characterized the post stroke immune 
response with respect to the spleen over time.  In this study, the shrinkage of the 
spleen was shown to be a transient phenomenon.  Splenocytes were found in the 
blood and thymus, but only in very low numbers to the brain.  Further analysis 
demonstrated that IL10 and IFNγ levels are increased following stroke.  
Treatment with DTG significantly decreased IL10 and IFNγ production in the 
spleen.  These experiments provide evidence that while the acute stress 
response induces the production of IL10 it cannot completely suppress IFNγ 
production.  Treatment with DTG significantly reduces this pro-inflammatory 
cytokine and decreases infarct volume.  
 
Materials and Methods 
Animal Care 
All animal procedures were conducted in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals with a protocol approved by the 
Institutional Animal Care and Use Committee at the University of South Florida. 
Timed pregnant Sprague-Dawley dams were purchased from Harlan Labs 
(Indianapolis, IN), maintained on a 12 hr light/dark cycle (7 am – 7 pm) and given 
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access to food and water ad libitum.  Neonatal rats birthed from time-pregnant 
dams were used for all experiments. 
 
Splenic injection of CFSE 
CFSE injections were performed five days prior to MCAO by making a 4 
cm dorsal midline skin incision at the caudal terminus at the level of the 13th rib. 
Opening the abdominal wall on the anatomical left, 1.5 to 2.5 cm from midline 
exposed the spleen. With blunt forceps, the organ, (with accompanying blood 
vessels and adipose tissue), was exteriorized through the incision.  CFSE (500μl 
total volume in DMSO) was injected into 5 evenly spaced sites along the spleen. 
The spleen was then reinserted into the animal and the wound was closed with 
sutures. 
 
Laser Doppler blood flow measurement 
Laser Doppler Radar (LDR) was used to monitor blood perfusion (Moor 
Instruments Ltd, Devon, England). A 2 mm diameter hole was drilled into the 
right parietal bone (1 mm posterior and 4 mm lateral from bregma), and a guide 
screw was set. The LDR probe (MP10M200ST; Moor) was inserted into the 
guide screw, and the tip of the probe was placed against the pial surface of the 
brain. Rats that did not show >55% reduction in perfusion during MCAO were 
excluded from the study. 
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Permanent Middle Cerebral Artery Occlusion  
MCAO surgery was performed using the intraluminal method originally 
described (Longa et al. 1989). Briefly, a filament (4cm long, 6lb test 
monofilament) was advanced into the internal carotid artery by way of the 
external carotid artery until it occluded the origin of the middle cerebral artery, 
and tied off at the internal/external carotid junction to produce permanent 
occlusion. The rat was then sutured, given a 1 ml subcutaneous injection of 
saline, and allowed to wake in a fresh cage. 
 
Brain Extraction and Sectioning  
The animals were euthanatized with 0.5 ml of pentobarbital at 96 hours, 
and perfused with saline and 4% paraformaldehyde. The brains were harvested, 
post fixed in paraformaldehyde, and immersed in 20% followed by 30% sucrose 
in PBS. Brains were frozen and sliced into 30μm sections with a cryostat. 
Sections were either thaw mounted on glass slides or placed in Walter’s Anti-
freeze cryopreservative. 
 
Fluoro-Jade Staining 
 Six coronal brain sections at 1 mm intervals were cut from 1.7 to -3.3 mm 
from Bregma for infarct quantification.  These sections were stained with Fluoro-
Jade (Histochem, Jefferson, AR), which labels degenerating neurons.  This 
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method was adapted from that originally developed (Schmued et al. 1997) and 
has been described by (Duckworth et al. 2005).  Sections were mounted and 
dried to glass slides.  Slides were rehydrated by then exposure to absolute 
ethanol for 3 min followed by 70% ethanol and deionized water for 1 min each. 
Slides were oxidized using a 0.06% KMnO4 solution for 15 min followed by three 
rinses of double distilled water for 1 minute each.  Slides were stained in a 
0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min.  Slides were  
rinsed, allowed to dry at 45 oC for 20 min, cleared with xylene and cover slipped 
with DPX mounting medium (Electron Microscopy Sciences, Ft. Washington, 
PA).  
 
Infarct Volume Quantification - Fluoro-Jade stained tissue was digitally 
photographed with an Olympus IX71 microscope controlled by DP manager 
software (Olympus America Inc, Melville, NY) at a magnification of 1.25X. 
Images were edited with Jasc Paintshop Pro. Area of neurodegeneration was 
measured using the NIH Image J software. The area of the contralateral side of 
the brain tissue was also measured and used to compensate for possible edema 
in the ipsilateral hemispheres. Infarct volumes were then calculated by the 
summation of the infarct areas. 
 
Immunohistochemistry  
The slides were rinsed with PBS (pH 7.2), and then placed in 
permeabilization buffer containing 10% goat serum, 3% 1M lysine, and 0.3% 
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Triton X-100 in PBS for 1 hr at room temperature.  Next, sections were incubated 
overnight at 4°C in a PBS solution with 2% goat serum and 0.3% Triton X-100 
and primary antibody in a humidified chamber, protected from light when 
necessary.  Slides were washed with PBS (3 x 5 min) and incubated with a 
secondary antibody solution (PBS, 2% goat serum, 0.3% Triton X-100, 
biotinylated goat anti rat (1/300))for 1 hour followed by avidin / biotin / 
horseradish peroxidase complex (Vectastain Elite ABC kit; Vector) for 1 h. 
Sections were washed 3x in PBS, and metal-enhanced 3, 3’-diaminobenzidine 
(Pierce, Rockford, IL) was used for color development. 
ELISA assay   
READY-SET-GO! ELISA kits (eBioscience) for IL10 and interferon-gamma 
were used to determine levels of these cytokines.  ELISAs were run according to 
manufacturer’s instructions.    
 
Results 
Infarct volumes peak by 24 hours in rats subjected to MCAO 
To characterize the progression of neurodegeneration following MCAO 
infarct volumes were determined by Fluoro-Jade staining at various timepoints 
following MCAO.  The timepoints studied were 3, 24, 48, 51, 72, and 96 hours 
post-MCAO.  No Fluoro-Jade staining was observed in sham operated animals 
or animals taken at 3 hours post MCAO.  Fluoro-Jade staining reached peak 
levels 24 hours post MCAO and remained elevated at all subsequent timepoints 
(Figure 1). 
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Figure 1.  Infarct volumes peak by 24 hours in rats subjected to MCAO 
Mean infarct volumes plotted over time following MCAO.  Infarct volumes were 
significantly increased from sham operated controls at the 24, 51, 72, and 96hour 
timepoints.  The three hour timepoint did not differ significantly from controls.  
Asterisk denotes significance at p<0.05 as determined by one-way ANOVA with 
a post hoc Dunnet’s test. 
 
Post-stroke shrinkage of the spleen is a transient phenomenon 
The spleen has been shown to shrink following MCAO.  As the spleen 
plays a critical role in infarct development, the size of the spleen was 
127 
characterized over time.  The timepoints studied were 3, 24, 48, 51, 72, and 96 
hours post-MCAO (Figure 2).  The spleen significantly decreased in size at the 
24, 48, and 51 hour timepoints compared to sham operated or 3 hr MCAO 
timepoint.  The spleen regained its size by 72 hours post-MCAO such that it was 
not different from the sham or 3 hr timepoint (p<0.01).   
 
Figure 2. The spleen shrinks transiently following MCAO 
Mean spleen weights plotted over time following MCAO.  Spleen weights were 
significantly decreased by the 24, 48, and 51hour timepoints.  Spleen weights 
were not significantly different from sham operated controls at the 3 72 and 
96hour timepoints. Asterisk denotes significance at p<0.01 as determined by 
one-way ANOVA with a post hoc Dunnet’s test using the sham operated animals 
as controls. 
128 
 
CFSE labeled splenocytes are present in various tissues following MCAO  
To determine if the shrinkage in spleen size was associated with an 
increase in spleen derived immune cells in the brain in vivo labeling of 
splenocytes was performed.  CFSE was injected into the spleens of animals five 
days prior to MCAO to label splenocytes.  Spleen (Figure 3A), blood (Figure 3B), 
brain (Figure 3C), and thymus (Figure 3D) of animals at different timepoints were 
assessed for CFSE positive cells.  CFSE staining was abundant in all tissues 
studied except brain, where CFSE stained cells were few and restricted to blood 
vessels in the infarct. 
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Figure 3. CFSE labeled splenocytes are present in various tissues following 
MCAO  
Representative sections from spleen (A), blood (B), brain (C), and thymus (D) at 
96 hours following MCAO.  CFSE staining was abundant in all tissues studied 
except brain where CFSE stained cells were few and restricted to blood vessels 
in the infarct. 
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IL10 immunostaining is increased in the brain and spleen following MCAO 
IL10 production in the infarct was characterized over time in MCAO 
treated rats.  IL10 immunostaining was performed on brain sections from 24 
hours (Figure 4A), 51 hours (Figure 4B), 72 hours (Figure 4C), and 96 hours 
(Figure 4D) following MCAO.  Mean values plotted over time demonstrate a 
significant increase in IL10 at the 96 hour timepoint compared to the 24 hour 
timepoint (Figure 4E).  Mean concentrations of IL10 in the spleen over time 
(Figure 4F) demonstrate a significant (p<0.0?) increase in IL10 protein by the 96 
hour timepoint.  Mean concentrations of IFNγ in the spleen over time (Figure 4G) 
demonstrate a significant increase (p<0.05) in IFNγ protein by the 96 hour 
timepoint.     
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Figure 4. IL10 and IFNγ expression increases over time following MCAO 
Representative sections stained for IL10 from the 24 (A), 51 (B), 72 (C), and 96 
(D) hour timepoints following MCAO.  Mean IL10 immunostaining in brain plotted 
over time (E) reveals a significant increase at the 96 hour timepoint.  Mean 
concentrations of IL10 in the spleen over time (F) demonstrates a significant 
increase in IL10 protein by the 96 hour timepoint. Mean concentrations of IFNγ in 
the spleen over time (G) demonstrates a significant increase in IFNγ protein by 
the 96 hour timepoint. Asterisk denotes significance at p<0.05 as determined by 
one-way ANOVA with a post hoc dunnet’s test using the 24 hour timepoint as 
control. 
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DTG or HUCBC treatment reduces IL10 and IFNγ following MCAO 
As IL10 production is known to be induced by DTG and HUCBC therapies, 
96hr timepoint brain sections from animals treated with vehicle (Figure 5A), 
HUCBC (Figure 5B), or DTG (Figure 5C) were immunostained for IL10 
production.  Quantification of immunoreactivity demonstrated that IL10 
production was significantly reduced (p<0.05) in animals treated with DTG and 
HUCBC when compared to vehicle (Figure 5D). Mean concentrations of IL10 
protein as measured by ELISA show that DTG treatment significantly decreased 
IL10 production in the spleen (p<0.05) following MCAO (Figure 5E) Mean 
concentrations of IFNγ protein as measured by ELISA show that DTG treatment 
significantly suppressed IFNγ production in the spleen (p<0.05) following MCAO 
(Figure 5F). 
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Figure 5. DTG and HUCBC treatment reduces IL10 and IFNγ following 
MCAO 
Representative sections from animals treated with Vehicle (A), HUCBC (B), and 
DTG (C) and sacrificed at the 96hr timepoint were immunostained for IL10 
production.  Quantification of immunoreactivity demonstrated that IL10 
production was significantly reduced in the animals treated with DTG and 
HUCBC when compared to vehicle (D). Mean concentrations of IL10 protein as 
measured by ELISA shows that DTG treatment significantly decreases IL10 
production in the spleen following MCAO (E). Mean concentrations of IFNγ 
protein as measured by ELISA shows that DTG treatment significantly 
suppressed IFNγ production in the spleen following MCAO (F).  Asterisk 
represents significance at p<0.05 as measured by one-way ANOVA with post 
hoc Bonferroni’s test. Pound symbol indicated significance at p<0.05 as 
measured by students t-test. 
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Discussion 
The peripheral inflammatory response to brain injury is tightly regulated.    
IL1β, TNFα, and IL6 released in response to brain injury stimulate centers in the 
locus ceruleus to induce neural sympathetic activation.  Activity of these 
cytokines also causes the release of CRH in the hypothalamus (Chrousos 1992). 
Furthermore reciprocal activation can occur based on neural crosslinks between 
the lateral paraventricular nucleus and the locus ceruleus (Saper et al. 1976).  
 Release of epinephrine from the adrenal glands in response to CRH, in 
addition to the direct secretion of norepinephrine into the lymphoid organs by 
sympathetic nerve fibers suppresses immune cell function and promotes the 
release of TH2 cytokines such as IL10.  Circulating catecholamines and 
glucocorticoids alter the morphology of peripheral lymphoid organs known to be 
involved in the progression of stroke, such as the spleen (Elenkov et al. 2000).   
Experiments were performed to characterize the infarct and the size of the 
spleen over time following MCAO.  The infarct progressed rapidly from 
essentially no infarction at three hours to 60% of the ipsilateral hemisphere being 
infarcted by 24 hours.  This is reflected in the spleen size as well, with spleens 
not being significantly smaller than sham controls at 3 hours while decreased in 
size by 30% by 24 hours.  Interestingly, while infarct volume plateaued at levels 
seen at the 24 hr timepoint, spleen weights were recovered by 72hrs such that 
they were not different from controls.  This suggests that the catacholaminergic 
135 
stress response is a transient phenomenon which is counteracted by some 
mechanism by 72 hours following MCAO. 
As the change in spleen size has been associated with alterations in 
splenic composition (Offner et al. 2006a), the cellular trafficking of splenocytes 
into the brain was studied.  Cells within the spleen were labeled with the cell 
tracer CFSE prior to MCAO.  While CFSE labeled cells were found in the blood, 
spleen, and thymus, at no timepoint observed were labeled cells found in 
appreciable numbers in the brain parenchyma.  The only CFSE labeling 
observed was restricted to blood vessels and the number of cells seen was less 
than 10 per brain section.  This was surprising as removal of splenocytes via 
splenectomy reduces infarct volume by 80%.  This suggests that the role of the 
splenocytes in ischemic injury is indirect.  One possible mechanism for 
splenocytes to alter infarct volume without entering the brain is through antigen 
presentation.  It is known that dendritic cells home to the spleen upon activation 
by antigen.  As ischemic brain injury releases CNS specific antigens such as 
myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG) 
dendritic cells could present these proteins to T-cells in the spleen and induce a 
more potent inflammatory response.  This theory is supported by studies using 
mice deficient in T-cells which have markedly reduced infarct volumes (Yilmaz et 
al. 2006), and in studies in which mice passively tolerized with MOG (Frenkel et 
al. 2003) and MBP (Gee et al. 2008) show reduced infarct volumes . 
If the response of the spleen to stroke is mediated by modulation of the 
peripheral immune system, one mechanism by which this could be accomplished 
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is through the secretion of cytokines such as IL10 and IFNγ.  These cytokines 
can shift the immune system into a TH2 or a TH immune response, respectively.  
Therefore, the final set of studies examined the production of cytokines over time 
following MCAO. IL10 immunostaining was found to be markedly increased in the 
infarct beginning at 51 hours and increasing significantly by 96hours.  This 
immunostaining was primarily neuronal in origin suggesting that these cells are 
responding to inflammation by releasing this anti-inflammatory cytokine.  IL10 
can suppress the release of TNFα and IL1β (Chrousos 1995), so the observed 
increases in the levels of this cytokine in the brain following MCAO may be 
responsible for the return of the spleen size to sham control levels.  IL10 and 
IFNγ production both increased significantly in the spleen over time.  This 
suggests that there is an active inflammatory response which the body is trying to 
suppress. 
Interestingly, both HUCBC and DTG treatments significantly reduced IL10 
and IFNγ levels in the brain.  Both treatments are potently anti-inflammatory and 
have been associated with increased IL10 production.  This may be explained by 
the fact that both treatments significantly decreased infarct volumes.  If IL10 
production was a response to inflammation mediated by such as IFNγ, then it is 
logical that treatments which reduce this inflammation would reduce IL10 
production in both the brain and the spleen. 
Ischemic brain injury is a dynamic process. In this study, we characterized 
the body’s response to ischemia over time.  The observations gathered here lend 
insight into the interplay between the brain and spleen in response to injury.  As 
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the peripheral immune system plays an important part in the body’s response to 
ischemia, an understanding of how the spleen fits into this role is important to 
identify therapeutic targets at delayed timepoints following MCAO 
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Chapter 5 
Conclusions 
 
  As our population ages and the quality of medical care improves, a greater 
proportion of stroke victims survive.  Many of these survivors are functionally 
disabled, requiring assistance to perform basic tasks necessary for 
independence.  The costs to the survivor both financially and emotionally are 
devastating.  As two-thirds of stroke survivors are over the age of 65, most of 
these survivors are enrolled in public medical programs such as Medicare.  The 
costs to these programs, and thus to the public, are enormous.  
 Currently there is only one FDA approved treatment for stroke, tissue 
plasminogen activator (rTPA).  This treatment yields significant improvements in 
stroke outcome with a 13% increase in favorable outcome functionally in patients 
eligible for this treatment.  Therein lays the major caveat for this treatment.  In 
order to be eligible for rTPA, patients must get to the hospital, be diagnosed, and 
have a CT scan to rule out hemorrhagic stroke within 3 hours of symptom onset 
in order to be a candidate for therapy.   Due to this very narrow therapeutic 
window, only 3-5% of stroke sufferers are eligible for this treatment.  Thus, there 
is an immense need for therapies which can treat stroke effectively at delayed 
(24-48hr), clinically relevant, timepoints. 
 The heady exuberance with which the stroke field embraced excitotoxicity 
has largely been replaced with a painful hangover of failed clinical trials and 
millions of dollars wasted.  While it may be possible to treat stroke by reducing 
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excitoxicity from a theoretical standpoint, from a clinical standpoint it is obvious 
that these processes occur too early on for the patient to arrive for treatment in a 
timely manner.  The goal of stroke treatment now is to fundamentally alter the 
body’s response to stroke and unlimber the potent innate repair mechanisms in 
order to reverse ischemic brain injury and produce functional recovery.  To 
accomplish this it is imperative to look beyond the first 6 hours of ischemia and 
gain a deeper understanding of the biology of ischemic injury at these delayed 
timepoints.  Essential to this is the identification of treatments which are effective 
at delayed timepoints (24-48 hours post stroke).  With such treatments it is then 
possible to identify the systems through which they act to winnow out potential 
targets for stroke therapy. 
In order to treat stroke at 24 to 48 hours, it is as important to address the 
immune response to the infarction as it is to treat the infarction it self.  This can 
be achieved in two ways: a cocktail of drugs targeting both inflammatory and 
neurodegenerative processes, or a single treatment which has multiple effects 
limiting both the immune response and neurodegeneration.  As polypharmacy 
treatment increases the propensity for side effects via drug-drug interactions; a 
single therapy is more attractive for the treatment of patients in a frail state 
induced by stroke. 
 Two such therapies which have shown promise in the MCAO model of 
stroke are HUCBC and DTG.  Both of these therapies reduce infarct volumes by 
50% or more and are effective when administered 24hrs post MCAO.  The 
mechanism by which these therapies are neuroprotective is unclear.  Both 
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treatments decrease ischemic neuronal death and suppress inflammation in vitro 
and decrease peripheral inflammation in vivo.   As there are multiple systems 
which could mediate the beneficial effects of these therapies, it is important to 
identify which system is responsible for the observed reductions in infarct 
volumes.  The experiments described here sought to clarify whether these 
therapies actively altered inflammatory processes in the CNS or the periphery 
and the relative contributions of both sources of inflammation on ischemic 
neuronal death.  
 It was clear from the studies performed in aim 1 that sigma receptor 
activation reduces microglial activation at multiple levels, including the 
morphological, migratory and inflammatory responses to several agents that 
trigger these responses in microglia. The results of this study provide insight into 
the role of sigma receptors in the regulation of immune system function.  As 
these processes are critical to the microglial response to injury, these findings 
reveal a novel aspect of the modulation of microglial activation by sigma 
receptors. Furthermore, these findings directly translate into effects this treatment 
may have on other monocyte derived cells as well. 
Blood born monocytes which are precursors to microglia and 
macrophages can react to cellular debris generated by the initial ischemic insult 
via activation of toll-like receptors.  This can induce the transformation of these 
monocytes into dendritic cells which can then present CNS antigens to 
lymphocytes in the spleen and activate the adaptive immune system. 
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Invasion of peripheral macrophages is seen in ischemic injury beginning at 
24hours and peaking by 3 days.  In both cell types sigma receptor activation 
likely reduces chemokine induced migration and activation of toll-like receptor 
signaling in a similar manner to that seen with microglia. 
Our results demonstrate that sigma receptor activation blocks changes in 
actin aggregation in response to ATP application.  Metabotropic P2Y12 
receptors, which evoke increases in [Ca2+]i in microglia (Ohsawa et al. 2007), are 
critical to the induction of membrane ruffling by ATP exposure (Honda et al. 
2001).  In our migration studies we saw robust migration in response to ATP 
(which is mediated by P2Y12 receptors as well) and MCP-1, both of which 
induce migration through a pertussis toxin sensitive Gi/o-protein (Dzenko et al. 
2001; Honda et al. 2001; Sozzani et al. 1994).  Migration induced by both 
chemoattractants was inhibited by sigma receptor activation, suggesting that 
sigma receptors inhibit migration either by direct interaction with the Gi/o-protein 
or by interfering with downstream calcium signaling.  
Chemokine signaling is a major mechanism by which local and peripheral 
immune ells are recruited to sites of injury.  Microglia, neutrophils, dendritic cells, 
lymphocytes and monocytes all use chemokine gradients to migrate to sites of 
injury.  Inhibiting chemokine signaling downstream of the receptor is a powerful 
mechanism by which sigma receptor activation can reduce immune cell 
infiltration into the infarct. 
P2Y12 receptors not only mediate ATP induced migration in microglia, but 
they are also found on the surface of platelets where they promote adhesion and 
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clot formation. Inhibition of platelet P2Y12 receptors via clopidogrel reduces the 
formation of blood clots in patients at risk for stroke and myocardial infarction 
(MI).  As stroke and MI survivors are at an increased risk for a subsequent 
stroke, inhibition of P2Y12 receptors on platelets by DTG would be not only 
protective acutely but also prophylactically.  
  Activation of sigma receptors in the peripheral immune system has been 
shown to potently suppress the inflammatory response to a variety of stimuli 
(Bourrie et al. 2002).  It was proposed that these anti-inflammatory effects were 
mediated by sigma receptor-induced interleukin-10 (IL10) production (Zhu et al. 
2003a).  However, studies on sigma receptor-mediated immunosuppression in 
RAW 264.7 macrophages suggested that IL10 is not always involved in these 
responses (Gannon et al. 2001).  This latter observation is consistent with our 
finding that IL10 production in response to LPS treatment was decreased with 
similar kinetics to reductions of TNF-α and NO production.  This observation 
implies that sigma receptor activation affects signaling upstream of protein 
synthesis-dependent processes in the inflammatory response.    
Sustained increases in basal intracellular calcium levels are integral to the 
induction of the inflammatory response (Hoffmann et al. 2003) in microglia after 
stimulation with LPS.  Stimulation of toll-like receptors by LPS mimics the 
stimulation of this receptor by cell debris which is present in the infarct.  Sigma 
receptor activation reduces the capacity of microglia to generate this sustained 
increase in calcium in response to LPS.    This is associated with a decreased 
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release of cytokines and NO.  Reintroduction of calcium with ionomycin 
overcame the sigma receptor activation induced blockade of NO production. 
Our results in aim 1 show that activation of sigma receptors suppresses 
microglial activation primarily by inhibiting calcium signaling.  Calcium is a critical 
signaling molecule in immune cells suggesting that the immunosuppressive 
effects of this receptor are not necessarily restricted to only microglia. 
Neurosteroids, such as progesterone and estrogen, bind to sigma receptors with 
high affinity and are associated with decreased immune responsiveness (Su et 
al. 1990).  Our findings raise the intriguing possibility that these sigma ligands are 
exerting central effects via the activation of sigma receptors (Su 1991). Since 
astrocytes synthesize dehydroepiandrosterone (Zwain and Yen 1999), another 
endogenous sigma ligand, the presence of sigma receptors on microglia may 
represent a pathway by which microglial activation may be suppressed locally by 
support cells.        
Activated microglia have been associated with neurodegenerative disease 
progression (Streit et al. 2004), and the presence of a significant number of 
activated microglia has been linked to increased neuronal damage.  In contrast, 
ablation of microglia is also associated with increased damage (Lalancette-
Hebert et al. 2007), which shows that microglia play a complex part in the 
etiology of neurodegenerative disease.  As microglia have the capacity to either 
promote neurodegeneration or neurosurvival, the microglial response to injury is 
a highly regulated process. Our findings support and expand upon the theory that 
sigma receptors have potent immunoregulatory properties (Bourrie et al. 1995; 
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Bourrie et al. 2002).  Interestingly sigma receptor activation in microglia has also 
been associated with increased TGFβ production (Gekker et al. 2006).  TGF-B is 
an anti-inflammatory cytokine that is important in the induction of tolerance to 
antigens.  As circulating monocytes that encounter cell debris mature into antigen 
presenting dendritic cells following MCAO, increased TGFβ signaling may impair 
this process.  Furthermore, TGFβ is known to enhance wound healing and 
neurosurvival which could further explain the observed reductions in infarct 
volume following MCAO. 
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Figure 1. Sigma receptor agonists suppress microglial activation by 
interfering with intracellular calcium signaling.  Microglial activation is a 
complex multi step process. Upon detection of a damage signal or invading 
pathogen via chemoreception, a transient calcium increase occurs.  Following 
this, microglia rapidly rearrange their actin cytoskeleton and withdraw their 
processes.  They then migrate to the site of injury.  Upon prolonged stimulation 
the basal levels of intracellular calcium increase in the microglia, which 
decreases their ability to generate the large calcium transients in response to the 
chemoattractant serving as an endogenous stop signal.  Once at the site of 
injury, microglia can then release cytokines and reactive oxygen species 
depending on the tissue microenvironment.  Sigma receptor activation 
suppresses the transient and sustained calcium increases necessary for these 
processes, blocking microglial activation.   
In aim 2 organotypic slice cultures were used to study the observed effects of 
sigma receptor activation on microglia were neuroprotective in the absence of the 
peripheral immune system.  Organotypic hippocampal slice culture is a superior 
model for the study of ischemic brain injury than dissociated cell cultures owing 
to the fact that all brain cell types are present with functional connections 
(Noraberg et al. 2005). The multiple inflammatory stimuli released by ischemic 
neurons in the slice cultures activate microglia by a mechanism which mimics the 
in vivo ischemic microenvironment more closely than traditional activators such 
as lipopolysaccharide.  In order to further characterize this model with respect to 
neurodegeneration, slice cultures were subjected to OGD at different timepoints 
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and stained with Fluoro-Jade.  In this model system neurodegeneration 
increased in a time dependant manner following the induction of OGD with 
significant increases observed at the 48hr timepoint.  
In this study the HUCBC treatment was neuroprotective but the DTG 
treatment was not.  This is intriguing as sigma receptor agonists reduce ischemia 
and acidosis induced death in dissociated neuronal cultures by reducing calcium 
influx into these neurons (Herrera et al. 2008; Katnik et al. 2006).  Furthermore 
sigma agonists suppress spreading depression and ionic imbalances in acute 
hippocampal slice preparations (Anderson and Andrew 2002; Anderson et al. 
2005).  As spreading depression and calcium dysregulation are central 
components of excitotoxic cell death, blocking these processes with DTG should 
have resulted in reduced Fluoro-Jade staining in slices subjected to OGD.   This 
demonstrates that in this model, blocking excitotoxic cell death, anoxic 
depolarization, and microglial activation directly is not sufficient to protect 
neurons.   
Intriguingly, similar effects are noted in vivo.  Administration of 
dehydroepiandrosterone, a potent sigma receptor agonist, reduced ischemic 
infarct volume when administered 6-36 hours following stroke.  When DHEA was 
administered prior to or 1 hour after stroke it significantly increased 
neurodegeneration.  Both effects were found to be due to activation of the sigma-
1 receptor.  Excitotoxicity associated phenomena such as NMDA receptor 
activation are thought to occur within the first hour of stroke onset. Therefore it 
seems unlikely that the prevention of excitotoxicity or the blockade of microglial 
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activation is the mechanism by which DTG reduces infarct volume following 
stroke. 
Sigma receptors also have potent anti-inflammatory properties which can 
reduce inflammation induced neuronal death.  In the organotypic slice culture 
microglia are the only immune cell type present.  Sigma receptors reduce 
microglial activation in vitro by suppressing intracellular calcium signaling (Hall et 
al. 2008).  By blocking intracellular calcium signals, many aspects of microglial 
activation such as membrane ruffling, migration, and cytokine production are 
impaired (Hall et al. 2008).  The 300μM DTG concentration, which completely 
suppressed microglial activation (Hall et al. 2008), resulted in the highest levels 
of Fluoro-Jade staining encountered, suggesting that some aspects of microglial 
activation are beneficial. This finding is in agreement with other studies which 
have shown that ablation of microglia is neurodestructive (Lalancette-Hebert et 
al. 2007). 
While HUCBC treatment has been shown to reduce propidium iodide 
uptake in organotypic slice cultures, no studies have been performed to our 
knowledge which directly measure neuronal damage or the ensuing inflammatory 
response (Vendrame et al. 2005).  HUCBC treatment reduced both 
neurodegeneration and microglial mediated inflammation.   HUCBC significantly 
decreased the number of microglia which expressed NO.  This is in agreement 
with the finding that HUCBC therapy in vivo dramatically reduced the number of 
microglia present in the infarct (Newcomb et al. 2006). Similar experiments using 
this model demonstrated that the MMP inhibitor AG3440 also reduced 
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neurodegeneration in this model (Leonardo et al. 2009).   MMP9 can reduce 
neuronal viability directly by degrading the extracellular matrix and inducing 
anoikis.  As these treatments were given at the time of OGD it is unclear whether 
these treatments reduced microglial activation directly or indirectly by reducing 
neuronal death.  Based on the data from DTG it seems likely that activated 
microglia are not the cause but a byproduct of OGD induced neurodegeneration. 
The studies from aim 2 show that sigma receptor activation on ischemic 
brain tissue is not directly protective, suggesting that the target of this therapy is 
peripheral to the CNS.  Sigma receptor activation suppresses T-cell mediated 
immunity by upregulating production of the anti-inflammatory cytokine IL10 (Zhu 
et al. 2003b).  As microglia can interact with T-cells as antigen presenting cells 
(Morioka et al. 1991), it is possible that modulation of this interaction by sigma 
receptor agonists such as DTG could result in the robust neuroprotection seen in 
vivo. The results shown here suggest that the neuroprotection mediated by DTG 
in vivo at delayed timepoints is mediated by effects on systems outside of the 
CNS such as the peripheral immune system. A likely therapeutic target is the 
lymphocytes which infiltrate the infarct at delayed timepoints (Gee et al. 2007).  
This interaction of peripheral immune cells and injured brain tissue could also 
mediate the protective effects of HUCBC seen in this study as they are 
composed primarily of lymphocytes and monocytes (Pranke et al. 2001), and that 
migration into the CNS is not required for this protection (Borlongan et al. 2004).   
In aim 3, the systemic response to stroke was more closely studied. 
Experiments were performed to characterize the infarct and the size of the 
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spleen over time following MCAO.  The infarct progressed rapidly from 
essentially no infarction at three hours to 60% of the ipsilateral hemisphere being 
infarcted by 24 hours.  This is reflected in the spleen size as well, with spleens 
not being significantly smaller at 3 hours than sham controls while by 24 hours 
the spleen decreased in size by 30%.  Interestingly while infarct volume 
plateaued at levels seen at the 24hr timepoint spleen weights were recovered by 
72hrs such that they were not different from controls.  This suggests that the 
catacholaminergic stress response is a transient phenomenon which is 
counteracted by some mechanism by 72 hours following MCAO. 
As the change in spleen size has been associated with alterations in 
splenic composition (Offner et al. 2006), the cellular trafficking of splenocytes into 
the brain was studied.  Cells within the spleen were labeled with the cell tracer 
CFSE prior to MCAO.  At no timepoint observed were labeled cells observed in 
appreciable numbers in the brain parenchyma.    This was surprising as removal 
of splenocytes via splenectomy reduces infarct volume by 80%.  This suggests 
that the role of the splenocytes in ischemic injury is indirect.  One possible 
mechanism for splenocytes to alter infarct volume without entering the brain is 
through antigen presentation.  It is known that dendritic cells home to the spleen 
upon activation by antigen.  As ischemic brain injury releases CNS specific 
antigens such as myelin basic protein (MBP) and Myelin oligodendrocyte 
glycoprotein (MOG) dendritic cells could present these proteins to T-cells in the 
spleen and induce a more potent inflammatory response.  This theory is 
supported by studies using mice deficient in T-cells which have markedly 
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reduced infarct volumes (Yilmaz et al. 2006), and in studies in which mice 
passively tolerized with MOG (Frenkel et al. 2003) and MBP (Gee et al. 2008) 
show reduced infarct volumes . 
The final set of studies examined the production of cytokines over time.  
IL10 immunostaining was found to be markedly increased in the infarct beginning 
at 51 hours and increasing significantly by 96hours.  This immunostaining was 
primarily neuronal in origin suggesting that these cells are responding to 
inflammation by releasing this anti-inflammatory cytokine.  IL10 can suppress the 
release of TNFα and IL1β (Chrousos 1995), so the observed increases in the 
levels of this cytokine in the brain following MCAO maybe responsible for the 
return of the spleen size to the pre-stroke condition.  IL10 and IFNγ levels in the 
spleen also increased over time.  As IFNγ is a very potent activator of 
lymphocytes and macrophages, the fact that its levels increase over time 
suggests that there is still an ongoing inflammatory response which the body is 
responding to by upregulating IL10. 
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Figure 2. Changes in spleen size and content over time reflect an evolving 
interaction between the brain and immune systems following MCAO. The 
spleen, by virtue of the α1-adrenergic receptors on its smooth muscle capsule 
serves as a convenient maker of the acute stress response.  Increased 
circulating catecholamines bind to these receptors and cause the spleen to 
substantially decrease in size between 3 and 24 hours following MCAO.  These 
same catecholamines act on β2-receptors located on circulating monocytes to 
induce the release of IL10.  Levels of splenic IL10 increase between 24 and 48 
hours and remain elevated 96 hours post MCAO.  IL10 reduces inflammation in 
systemically which in turn causes the acute stress response to resolve.  This 
likely occurs between 48 and 72 hours following MCAO as the spleen regains its 
previous size during this interval.  Removal of the anti-inflammatory 
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catecholamine signaling induces a rebound in pro-inflammatory IFNγ production 
in the spleen. 
 
HUCBC and DTG treatments significantly reduced IL10 levels in the brain.  
Both treatments are potently anti-inflammatory and have been associated with 
increased IL10 production.  This disparity may be explained by the fact that both 
treatments significantly decreased infarct volumes.  If IL10 production by neurons 
was a response to inflammatory damage, then it is logical that treatments which 
reduce this inflammation would reduce neuronal IL10 production.  IL10 and IFNγ 
levels in the spleen were also significantly inhibited by DTG 96 hours post 
MCAO.  This likely reflects the fact that the majority of catecholamine induced 
IL10 is produced by monocytes (Woiciechowsky et al. 1998), a process which is 
inhibited by DTG (Hall et al. 2008). 
Taken together the data presented here present an interesting view of 
stroke induced injury and the relative contributions of the various factors 
involved.  Following the initial induction of ischemia excitotoxic processes 
damage neurons.  These neurons are protected from immediate neuronal death 
by the concerted actions of microglia and astrocytes.  If recanalization can be 
achieved at this point (such as with rTPA administration) the total damage can be 
significantly reduced.  This is effective out to approximately 6 hours following 
occlusion.  After this time, inflammatory cytokines induce the acute stress 
response via HPA axis activation.  This response causes the spleen to shrink 
and reduces TH1 immune responses.  TH2 responses such as IL10 production 
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increase starting at 24 hours in the spleen and brain.  IL10 is released rapidly 
from blood borne monocytes following β2-adrenergic receptor stimulation 
(Woiciechowsky et al. 1998).  This anti-inflammatory cytokine likely acts on brain 
centers in the hypothalamus and brain stem to shut down the acute stress 
response by 72 hours. The decreased catecholamine signaling allows the spleen 
to regain its size and removes the tonic immunosuppressive stimulus on 
circulating lymphocytes.   These lymphocytes have likely been migrating to the 
infarct and interacting with antigen presenting cells in the spleen and brain.  In 
the absence of the stress response, these cells begin producing TH1 type 
cytokines.  In the spleen this is reflected by the rebound in IFNγ seen between 48 
and 96 hours post MCAO.  This correlates with increased IL10 expression in the 
brain but not with a second induction of the acute stress response.  This implies 
that the inflammatory signaling at this time point is not mediated by TNFα, IL1β, 
and IL6.  This second inflammatory response is likely a T-cell mediated event 
and likely leads to the cell mediated clearance of compromised neurons from the 
infarct. 
DTG and HUCBC likely interfere with the ability of the peripheral immune 
response to continue following cessation of the acute stress response.   HUCBC 
can not only suppress inflammation but can also interrupt the acute stress 
response leading to early recovery of spleen weight.  The therapeutic target for 
DTG is likely T-cells which upon sigma receptor activation switches from a TH1 
(IFNγ producing) to a TH2 (IL10 producing) phenotype.  Sigma receptor 
activation likely suppresses macrophage and monocyte function similarly to 
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microglia. T-cells, however, have been implicated as the cell type which are 
necessary for ischemic injury (Yilmaz et al. 2006). 
 
Implications and Future Directions 
  The immune system is a promising target for the treatment of stroke 
induced brain injury.  The results from this set of studies further clarify the role of 
the immune system in ischemic brain injury, and the mechanisms by which 
delayed treatments for stroke function.  Timing of immunomodulatory therapies is 
critical for their success.  HUCBC therapy is good example of this, HUCBC must 
be transplanted during the acute stress response for efficacy (Newcomb et al. 
2006).  DTG likely has a similar requirement, as sigma receptor activation by 
DHEA is neuroprotective when administered at delayed (6-36 hour) but not 
hyperacute (<1 hour) times following ischemia (Li et al. 2009).  By studying 
HUCBC and DTG, and their effects on ischemic injury both in vivo and ex vivo, it 
was possible to determine that microglial activation following ischemic injury is 
not necessarily deleterious in the absence of the peripheral immune response.  
This perhaps explains why in a splenectomized animal there is a greatly reduced 
infarct.  Rats lacking a spleen still have activated microglia in their infarcts, 
however by 96 hours these cells become ramified and likely do not contribute to 
neuronal death (Ajmo et al. 2008).   
Furthermore, as DTG was neuroprotective only in the presence of the 
peripheral immune system suggests that modulation of this system is an ideal 
target for the treatment of stroke at delayed timepoints.  It is likely that while 
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HUCBC are neuroprotective in the absence of the peripheral immune system, 
their main mechanism for action is also on the peripheral immune system.  Three 
facts support this contention: 1, HUCBC are more effective when administered 
intravenously than when administered intrastriataly, 2, HUCBC are most 
efficacious at 48 hrs a timepoint at which the peripheral immune system is 
actively infiltrating the brain, and 3, HUCBC do not further decrease infarct 
volume in splenectomized rats suggesting that the direct effects of HUCBC on 
the ischemic brain tissue is minimal.   
Further studies will be needed to fully understand the role of the peripheral 
immune system at delayed timepoints following stroke.  One such study would be 
therapeutic splenectomy.  If splenectomy surgery 24 hrs post stroke was as 
efficacious as two weeks prior to stroke, it would demonstrate that excitotoxic 
processes are not as damaging as previously thought.  As these processes are 
still actively being targeted for stroke therapy, the results of this type of study 
would help refine future stroke therapies and improve the success rate in stroke 
treatment. 
158 
 
Figure 3. Successful therapeutic targets change as the body’s response to 
stroke changes over time.  The most important concept in stroke treatment is 
that stroke therapies must be applied at the proper stage in of the disease state.  
Therapies which are effective at reducing excitotoxicity or preventing infiltration of 
the parenchyma are likely are only going to be of benefit very early on in the 
disease progression, prior to the induction of the inflammatory response.  
Likewise administrations of anti-inflammatory treatments are not likely to be of 
benefit prior to the induction of the acute stress response.  This is because the 
acute stress response is neurologically protective and is induced by pro-
inflammatory cytokines.  Finally treatment for stroke at extremely delayed 
timepoints (>72 hrs) is likely to be limited to rehabilitation therapies which use 
various stimuli to promote axonal regeneration and partial gain of function. 
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